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ABSTRACT 
Background:  
Type II endometrial carcinoma, sarcoma and carcinosarcoma account for 10% of uterine 
malignancies but 50% of recurrences. Survival at recurrence is poor and better 
prognostic markers are needed to guide therapy. The prognostic significance of the 
novel markers clusterin and tetraspanin CD151 were evaluated in a cohort of poor 
outcome endometrial malignancies, along with oestrogen receptor, progesterone 
receptor, p53 and human epidermal growth factor receptor 2. Immunohistochemistry 
profiles and survival outcome between grade 3 endometroid cancers and type 2 cancers 
were compared. 
Material and Methods: 
Tissue microarrays constructed from 156 poor outcome uterine malignancies, tested 
with immunohistochemistry and staining were correlated with clinicopathological, 
mortality and survival data. 
Results:  
Expression of CD151 was significantly higher in uterine papillary serous and clear cell 
carcinoma (USPC+CC) compared to grade 3 endometrioid carcinoma, sarcoma or 
carcinosarcoma. All other markers were not prognostic for survival. Except for CD151, 
there was no significant difference in marker positivity, age, stage or survival between 
G3 EEC and UPSC+CC.  
Conclusion:  
CD151 is a novel marker in type 2 cancers that may guide therapeutic decisions. These 
data also suggest that grade 3 EEC is better characterised as a type II endometrial cancer 
and may benefit from similar treatment. 
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CHAPTER 
1 INTRODUCTION 
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1.1 Anatomy and histology of the uterus 
 
The uterus is a pear-shaped organ consisting of a fundus, body, isthmus and cervix. The 
fallopian tubes enter at each superolateral angle, above which lies the uterine fundus. 
The uterine body is flexed on the cervix (anteflection) while the whole uterus is tipped 
forward (anteversion). The uterus measures about 7.5 cm in length, 5 cm in breadth at 
its fundal end, and nearly 2.5 cm in thickness; it weighs between 30 to 40 g. 
 
 
Figure 1.1 
 
Anatomy of the uterus and adnexae. 
 
 
The uterus is divided into body (upper two-thirds) and cervix. The cervical canal 
traverses the internal os and emerges as the external os at the vaginal vault. The walls of 
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the uterus are composed of a mucosal layer (mucosa), the endometrium, and a 
fibromuscular layer, the myometrium (muscularis). The peritoneal surface of the uterus 
is covered by serosa. The myometrium is formed by layers of muscle fibres. The 
muscular tissue hypertrophies during pregnancy, and GAP-junctions between cells 
become more frequent. 
The endometrium consists of a simple columnar epithelium (ciliated cells and secretory 
cells) resting on a layer of connective tissue stroma. The endometrial mucosa is 
invaginated to form many simple tubular uterine glands. The glands extend through the 
entire thickness of the stroma. (Figure 1.2, see page 4) The stromal cells of the 
endometrium are embedded in a network of reticular fibres. In women of reproductive 
age, two layers of endometrium can be distinguished: The outer functional layer 
(functionalis) is the luminal part of the endometrium. This layer is built up following 
menstruation in the proliferative, first half of the menstrual cycle induced by oestrogen 
(follicular phase of menstrual cycle). Later changes in this layer are induced by luteal 
progesterone (luteal phase) providing an optimal environment for the nidation and 
growth of the embryo. This layer is shed during menstruation.  
The basal layer (basalis) is attached to the myometrium and below the functional layer. 
It is not shed during the menstrual cycle and forms the basis from which the functional 
layer redevelops at the beginning of every menstrual cycle. 
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Figure 1.2 
         
Normal uterine wall, hematoxylin & eosin staining: A. x200, with myometrium 
shown in lower half of the picture; B. x400, with invaginated gland extending 
through the thickness of the endometrial stroma. 
 
 
  
B A 
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1.2 Uterine malignancies – overview 
 
Uterine malignancies arise from the body of the uterus and can be broadly grouped into: 
• Endometrial carcinoma (90-95%) 
• Sarcoma of the uterus (3-7%) 
• Carcinosarcoma of the uterus (1%) 
The term endometrial cancer is often used to address every form of malignancy of the 
corpus uteri. However, it is actually a histopathological term exclusively referring to 
malignant tumours arising from the endometrium. Sarcomas are separately classified 
and staged. Carcinosarcoma or Malignant Mixed Mullerian Tumour (MMMT) used to 
be included in studies of uterine sarcoma and is classified as such by the World Health 
Organisation (WHO).1 However, carcinosarcomas are now believed to originate from a 
monoclonal carcinoma cell, and have recently been classified as metaplastic or 
dedifferentiated form of endometrial carcinoma. This has now been recognised by FIGO 
(International Federation of Gynecology and Obstetrics) and the current FIGO staging 2009 
of endometrial cancer includes carcinosarcoma. 2 3  
By convention, published literature on the epidemiology and survival from uterine 
cancer pertains to endometrial carcinoma only and does not include sarcoma and 
carcinosarcoma. In this study endometrial carcinoma, sarcoma and carcinosarcoma were 
included, thus their respective diagnosis, management and prognosis will be outlined in 
separate sections. 
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1.3 Endometrial carcinoma 
 
1.3.1 Epidemiology 
While the incidence and mortality rates from several other cancers have plateaued or 
decreased in the last decade the incidence of endometrial cancer has been rising 
throughout Europe and it is currently the most common type of gynaecological cancer. 4 
Worldwide it is the seventh most common cancer of women, with 189,000 new cases 
and 45,000 deaths each year and with the highest incidence rates in the Western world 
countries. 5 6  
In the United Kingdom endometrial cancer is currently the fourth most common cancer 
in women. A rapid increase by 40% has been observed since 1993, to an incidence of 
7835 in 2009 and 1937 deaths in 2010.7 
The age standardised incidence rate of endometrial cancer in the UK was 19.4 in 2008 
which compares to 16.2 in cancer of the ovary, 8.7 in cancer of the cervix and 2.4 in 
cancer of the vulva. In the majority (93%) of cases endometrial cancer is diagnosed in 
women aged over 50 years with only few women diagnosed under the age of 35. 
Incidence rises rapidly from just under 40 cases per 100,000 at the age of 50 to a peak 
of 83 per 100,000 females in their early seventies. Uterine cancer incidence rates 
decline after the age of 75. 
In the period 2005-2009, 77% of women in England survived their uterine cancer for 
five years or more. However, an increase in mortality has been observed. In the period 
between 1998 and 2010 the mortality rate of uterine cancers in the UK has risen by 
almost a fifth (17.9%) from 3.1 in 1997-1999 to 3.7 per 100,000 people in 2008-2010. 8  
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Furthermore, data from the United Kingdom West Midlands registry confirm more 
specifically that mortality in some groups of endometrial cancer has worsened.4   
Findings within the United States based Surveillance, Epidemiology and End Results 
database (SEER) study of more than 45,000 women with endometrial cancer, suggest 
that the increase in mortality may be related to an increased rate of advanced-stage 
cancers and high-risk histologies namely uterine papillary serous carcinoma (UPSC) 
and clear cell carcinoma.9 10 It is believed that the main causes for the observed increase 
in incidence and mortality in endometrial cancer are an increase in life expectancy, 
more women being overweight, having fewer or no children and tamoxifen use. 4 11 12  
 
1.3.2 Classification 
The most common endometrial cancer cell type is endometrioid adenocarcinoma (75-
80%), which is composed of malignant glandular epithelial elements. Sometimes an 
admixture of squamous metaplasia is also found. Adenosquamous tumours contain 
malignant elements of both glandular and squamous epithelium. Uterine papillary 
serous (UPSC) and clear cell (CC) carcinomas and tumour of mixed epithelial histology 
comprise approximately 14% of endometrial cancers. Mucinous, squamous and 
undifferentiated tumours are rarely encountered. The WHO classification and respective 
frequency of endometrial carcinoma cell types are outlined on the next page (Table 1.1, 
see page 8). 13 
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Table 1.1. 
 TYPES OF ENDOMETRIAL CARCINOMA 
1 Endometrioid (75%–80%) 
 a. Ciliated adenocarcinoma.  
 b. Secretory adenocarcinoma.  
 c. Papillary or villo-glandular.  
 d. Adenocarcinoma with squamous 
differentiation.  
2 Uterine papillary serous (<10%).  
3 Mucinous (1%).  
4 Clear cell (4%).  
5 Squamous cell (<1%).  
6 Mixed (10%).  
7 Undifferentiated.  
 
WHO classification and respective frequency of endometrial carcinomas. 
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1.3.3 Endometrial carcinoma and the dualistic model of 
endometrial tumourigenesis 
Apart from the FIGO classification which divides endometrial carcinoma solely into 
different histological types as described above, current concepts of endometrial cancer 
integrate traditional histopathology with pathogenetic mechanisms and the dividing line 
is the clinically relevant recognition of clinical outcome and prognosis.  
Endometrial cancer comprises not only the majority of tumours that respond well to 
treatment and confer a good prognosis but also a significant group of less common 
cancers that can be very aggressive, and account for a greatly disproportionate amount 
of deaths from uterine cancers. In 1983 Bokhman recognised this dilemma and 
postulated a classification of endometrial carcinomas into two types (Table 1.2, see page 
10). Although this classification is an oversimplification, it is currently a widely 
accepted concept. 14 
Type I endometrial carcinoma, is oestrogen dependent, of low grade endometrioid 
histology, biologically indolent and carries a good prognosis.  
Type II endometrial cancers are non-oestrogen dependent, of high grade, have various 
histologies, particularly papillary serous and clear-cell, and have a much poorer 
prognosis. 
1.3.3.1 Pre-cancers of the endometrium 
Endometrial carcinoma develops out of changes found in the endometrial surface 
epithelium. Both endometrial cancer types (endometrioid and serous cancer) have 
potentially precancerous precursor lesions preceding such changes. Their detection 
might be useful in diagnosis and treatment decisions.  
 10 
 
Other uterine malignancies which do not necessarily derive or present themselves in the 
endometrium, such as the group of sarcomas, carcinosarcomas (MMMT) and those of 
mixed epithelial or mesenchymal origin, have no known regular precursor lesions 
detectable via endometrial tissue sampling. 
However, even for the known endometrial cell alterations at risk of adenocarcinoma - 
the histologic definition of these precursor lesions and the degree of their risk is subject 
of ongoing controversy. Currently it is believed that there are – in concordance with the 
dualistic model of endometrial tumourigenesis also two types of different endometrial 
precancers which will be described in the following chapters. 15  
 
Table 1.2 
 TYPE I TYPE II 
   
Proportion of endometrial 
carcinomas 
80-90% 10-20% 
   
Age Pre-/perimenopausal > 60 yr 
   
Histology Endometrioid Papillary serous, clear cell, 
mixed epithelial 
   
Cell differentiation Grade I - III Not applicable 
   
Precursor lesion Hyperplastic EM Atrophic EM 
   
Oestrogen stimulation Dependent Non-dependent 
   
Clinical behaviour Indolent Aggressive 
 
The dualistic model of endometrial carcinomas - clinical and pathological features. 
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1.4 Type I endometrial carcinoma 
Synonymous: Endometrioid endometrial carcinoma (EEC).  
1.4.1 Precancer of type I endometrial carcinoma 
The current classification, adopted by both the WHO and the International Society of 
Gynecologic Pathologists (ISGP) was proposed by Kurman in 1985.16 Endometrial 
hyperplasia can be stratified into 4 groups according to the presence or absence of 
cytologic atypia and a degree of architectural complexity: 1. simple hyperplasia, 2. 
complex hyperplasia, 3. simple atypical hyperplasia, and 4. complex atypical 
hyperplasia. The rationale of this classification is based on the assumption that 
outcomes are different for the four groups. According to Kurman et al. likelihood of 
progression to cancer is 1% in patients with simple hyperplasia, 3% of those with 
complex hyperplasia, 8% of those with simple atypical hyperplasia, and 29% of those 
with complex atypical hyperplasia.16 However, reproducibility of the diagnosis of 
atypical endometrial hyperplasia is known to be less than 40%. Both underestimation 
and overestimation of the severity of the lesion is very common17-19 with a prevalence 
of concurrent carcinoma in women with a biopsy diagnosis of atypical endometrial 
hyperplasia between 17 and 50%.20-23 In 2000 the Endometrial Collaborative Group 
proposed the term, “endometrial intraepithelial neoplasia” (EIN) to characterize early 
malignant lesions.24 However, a recent large comparison study of the EIN system versus 
the WHO system showed similar risks of progression to carcinoma for diagnoses of EIN 
and atypical hyperplasia.25 
Developments in our understanding of the molecular genetic changes in pre-invasive 
endometrial disease call for a more quantitative, less subjective analysis of precancerous 
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endometrial lesions. The most commonly altered gene is phosphatase and tensin 
homolog (PTEN) a tumour suppressor gene with an important role in cell survival and 
possibly in cellular migration and adhesion.26 PTEN mutations are considered early 
events in type I tumourigenesis as they are found in up to 20% of endometrial 
hyperplasia cases (with and without atypia).27-29 Large scale studies however, have 
failed to show that loss of PTEN expression has the specificity and reproducibility to be 
clinically relevant.30 31 Additional significant and common genetic alterations in type I 
tumourigenesis include microsatellite instability (MSI) occurring in 20–45% of cases, 
K-ras mutation (10–30% of cases), and beta-catenin mutation (up to 20% of cases - with 
or without associated e-cadherin mutations).32 33 The presence of mutations of the 
tumour suppressor gene p53 is unusual in endometrioid endometrial carcinoma. 
However, if present, this may point to high grade histology. It is found in nearly 20% of 
FIGO grade 3 endometrioid tumours.34  
None of these markers have so far been able to significantly improve predictability of 
either endometrial precancerous lesions or an ensuing carcinoma development. In the 
future however, more readily available immunohistochemical and genetic testing may 
improve the currently used WHO classification and its predictability. 
 
1.4.2 Type I endometrial carcinoma 
Type I endometrial carcinomas represent the majority of sporadic cases of endometrial 
carcinoma, accounting for 70–80% of new cases which occur predominantly in pre- and 
perimenopausal women.35 36 Such cancers are typically of endometrioid type, generally 
of low-grade, low-stage, and indolent nature (Figure 1.3 A, see page 13). They have a 
good prognosis with a 5-year survival of more than 95%.  
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Figure 1.3:  
 
 
 
Hematoxylin & Eosin staining, x400, of endometrial carcinoma:  
A. Endometrioid endometrial carcinoma, grade 1;  
B. Uterine papillary serous endometrial carcinoma; 
C. Clear cell endometrial carcinoma. 
 
A 
B 
C 
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Type I endometrial carcinoma commonly express oestrogen and progesterone receptors. 
36 37 38  Thus, the associated risk factors are generally pro-oestrogenic, including obesity, 
high blood pressure, hyperlipidemia, and hyperoestrogenetic situations such as 
anovulation, nulliparity, infertility, oestrogen secreting tumours, late onset of 
menopause and endometrial hyperplasia. Long-lasting unopposed oestrogen exposure 
leads to endometrial hyperplasia, which increases the likelihood of development of 
atypical hyperplasia and eventually type I endometrial carcinoma. Type I endometrial 
carcinoma normally resembles proliferative rather than secretory endometrium.31 
Iatrogenic stimulation of the endometrium via tamoxifen- or prolonged oestrogen 
replacement therapy is another risk factor. Tamoxifen, a selective oestrogen receptor 
modulator (SERM), is a well known agent in the treatment of oestrogen receptor (ER) 
positive breast cancer with good evidence to improve both disease-free survival and 
overall survival. 39 The oestrogen receptor antagonist in the breast shows agonistic 
effects in the endometrium which is associated with a 2 to 7-fold increased risk of 
endometrial cancer.40 41 It is not clear whether there is an association between high or 
low grade endometrial cancer and tamoxifen use or whether the duration of its use has 
an influence on endometrial cancer grading. Presently the recommended duration of 
adjuvant treatment with tamoxifen for patients with breast cancer is 60 months and there 
are some reports relating the length of tamoxifen use with an increased risk of high risk 
endometrial cancer.42 43 
The rare mucinous carcinoma is also considered a type I endometrial carcinoma because 
they also usually express oestrogen and/or progesterone receptors and are of low 
histological grade.12 Immunostaining has been recommended as an adjunct in 
endometrial carcinoma subtype diagnosis but has not yet found its way into routine 
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practice. Chapter 1.9.3 will outline molecular characteristics that help to distinguish 
between type I and II endometrial carcinoma. 
 
1.5 Type II endometrial carcinoma  
Synonymous: Non-endometrioid endometrial carcinoma.  
1.5.1 Precancer of type II endometrial carcinoma 
The sequence of benign epithelium to dysplastic epithelium, to carcinoma in situ, and 
then to invasive carcinoma is commonly seen in the uterine cervix, breast, prostate, and 
other organs. In these tumours dysplastic epithelium frequently links the changes 
between normal epithelium and carcinoma in situ. Whilst the current model for 
dysplastic, precancerous lesions for type I endometrial cancer appears to be 
histologically sound and useful, putative precursor lesions to type II cancers are less 
well understood. 
Endometrial intraepithelial carcinoma (EIC) was previously considered as precancerous 
lesion for uterine papillary serous carcinoma (UPSC) defined as a non-invasive 
endometrial surface lesion with cytologic features identical to invasive serous 
carcinoma.44 However, many reported cases of EIC demonstrate concurrent invasive 
endometrial serous carcinoma, some of which are associated with intraperitoneal 
disease without identifiable invasive disease in the corpus. In a recent genome analysis 
9 out of 76 uterine serous carcinomas contained concurrent EIC. In all cases a 
concordant mutation status in PIK3CA, PPP2R1A, and TP53 was found.45 Thus it 
cannot be considered a precursor which, if diagnosed in time, could yield a therapeutic 
or even preventative benefit.46-48 EIC is now considered an early form of UPSC. 
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Endometrial glandular dysplasia (EmGD) has been suggested to be a potentially better 
candidate as a precancer to UPSC and clear cell carcinoma (CC).49 EmGD is 
characterized by replacing endometrial surface epithelium or its glands with dysplastic 
cells. It exhibits serous-like differentiation and has cytologic features that are more 
atypical than “resting endometrium” but cannot be considered a serous endometrial 
intraepithelial carcinoma (EIC). 
EmGD may be found in about 50% of UPSC, but it is rarely found in uteri containing 
typical endometrioid, i.e. type I endometrial cancer (EEC). It is also mainly found in 
postmenopausal women. This is in contrast to endometrial hyperplasia and endometrial 
intraepithelial neoplasia (EIN), which are more commonly associated with and 
preceding the occurrence of type I endometrial carcinoma lesions.49 50 Also, EmGD 
specimen show intermediate degrees of p53 expression which is believed to be one of 
the most characteristic genetic alterations in type II endometrial carcinoma and UPSC in 
particular. The presence or absence of p53 may be used to further distinguish EmGD 
between serous endometrial carcinoma and benign resting endometrium.51  
However, so far EmGD has not yet reached international recognition as a precancer of 
any form of type II endometrial cancer which leaves the clinician with virtually no tool 
to prevent the development of this cancer type and thus is a confounding factor for its 
poor performance along the diagnosis-treatment-survival axis.  
It has been proposed that there is more than only one tumourigenic pathway to reach 
type II endometrial carcinoma. McConnechy et al. performed mutation profiles from 9 
genes described to be associated with the development of type I or II endometrial 
cancer. They partly found mixed mutation profiles for uterine papillary serous cancers 
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which suggested different origins and pathways leading to clinico-pathologically similar 
tumours.52  
1.5.2 Type II endometrial carcinoma 
Type II endometrial carcinomas are far less common. Although these tumours only 
account for 10-20% of all endometrial malignancies,53 54  they are responsible for ~50% 
of all relapses55-57 and show a low 5-year, all stage, overall survival rate of 35%.53-58 
Histologically they are non-endometrioid, most frequently serous, less frequently clear 
cell and other histology, always high-grade in differentiation, typically arising in an 
atrophic endometrial background, and often have deep myometrial penetration. (Figure 
1.3 B, see page 13 and Table 1.2, see page 10) They usually occur at an older age, 
approximately 5 – 10 years later than type I tumours. There is no relationship to 
oestrogen stimulation. Clinically, type II endometrial carcinomas have an aggressive 
behaviour, with a high frequency of distant spread to pelvic lymph nodes. They are 
histologically partly similar to such tumours in the ovary and the fallopian tube, and the 
prognosis is worse compared to ovarian tumours.59 Small cell, undifferentiated, 
squamous cell and carcinomas of mixed histology may also be encountered among type 
II carcinomas, but little is known about their tumourigenesis.26 
 
1.5.2.1 Uterine papillary serous carcinoma (UPSC) 
UPSC is a highly malignant tumour representing about 10% of endometrial carcinoma 
characterised by a complex papillary serous architecture with tufted stratification of the 
epithelial lining, high nuclear to cytoplasmic ratio, notable nuclear pleiomorphism, 
macronuclei, and a high rate of mitosis. Morphologically it appears like an ovarian 
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serous papillary carcinoma, with similar intra-abdominal spread and frequently 
coincides with raised serum antigen CA125.60 (Figure 1.3 B, see page 13) These 
tumours characteristically do not express oestrogen or progesterone receptors and are 
often described to overexpress p53. 61 
The overall 5-year survival with a reported 18-27% is very poor. Survival in stage I-II is 
described to be 35-50%, decreasing to 0-15% in stages III-IV.56 There has been much 
debate about whether UPSC has a precursor lesion which might regularly precede the 
carcinoma thus potentially giving the opportunity for preventative action. Serous 
endometrial intraepithelial carcinoma (EIC) and endometrial glandular dysplasia 
(EmGD) have been identified as potential albeit controversial models and are discussed 
above in detail in chapter 1.5.1. So far there is no accepted precursor lesion which 
means there is no option to diagnose and treat a certain number of cases before the 
carcinoma has developed/disseminated and the prognosis is poor. Molecular changes 
observed in UPSC will be highlighted in chapter 1.9.4. 
 
1.5.2.2 Clear Cell Carcinoma 
About 5% of endometrial carcinoma is of clear cell histology. Clinical behavior and 
epidemiology is similar to uterine serous cancer. They also occur in the postmenopausal 
woman, are non-oestrogen dependent and not associated with obesity or diabetes. There 
is no precursor lesion clearly identified. Like UPSC, clear cell tumours are regarded as 
aggressive with a propensity for extra-uterine spread or relapse and have been reported 
to show extra-uterine deposits in the presence of clinically stage I disease occurring 
even without deep myometrial invasion. 62 
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Microscopically, clear cell carcinoma show tubulo-cystic, papillary or solid patterns, 
can have a clear appearance because of their high glycogen content, and may also 
include eosinophilic cells and hobnail cells (Figure 1.3 C, see page 13). 63 All cases are 
graded as poorly differentiated. However, clinical course and survival seem to be 
slightly better than with UPSC. 
Abeler et al. reviewed patients with clear-cell carcinoma and observed a 5-year survival 
for all stages as 42%, compared with 27% for UPSC. 61 Carcangiu and Chambers 
reviewed 29 cases of pathological FIGO stage I and II clear-cell carcinoma. They 
recorded a 5-year survival for stage I disease of 73% and 59% for stage II disease. 56 If 
surgically staged completely with bilateral pelvic lymphadenectomy survival figures are 
improving. 64 This obviously is partly due to an upstaging of a proportion of cases. 
However, Creasman et al. reported a 5-year survival of 81% for surgically staged stage I 
clear-cell carcinoma compared with 72% for uterine papillary serous carcinoma, and 
76% for grade 3 endometrioid cancers.62 P53 expression levels are reported to be 
intermediate between those in uterine papillary serous carcinoma and those in 
endometrioid cancers.63 
1.5.2.3 Tumours of Mixed Histology  
Endometrial carcinomas of mixed histology occur with an incidence of approximately 
10%. Given the fact that they are almost as common as UPSC or clear cell carcinoma 
together they are under-represented in studies and publications for mainly three reasons:  
They do not fit into the usual group-distinctions, like “endometrioid” or “UPSC”; hence 
are not classified by clear inclusion criteria. Pathologists may choose to classify them 
into the histological group dominant in the tumour rather than giving the term 
“mixed”.65 There is no uniformity in the literature, what the term “mixed” actually 
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constitutes – mixed epithelial, mesenchymal etc. Mixed epithelial tumours include 
various combinations of endometrioid-, clear cell-, and uterine papillary serous 
carcinoma. Cirisano et al. stated in a study of 574 patients that 18% had different post-
operative histological findings compared to pre-operative histology with more than 25% 
of the tumour volume of ambiguous histology.60 They also reported that tumours with 
mixed histology had a clinical behaviour comparable to that of uterine papillary serous 
carcinoma. However, in their report they did not state cases with mixed histology 
separately but grouped them under the three histologies; endometrioid, UPSC and CC. 
No details were given how this differentiation was made. 
The proportion of unusual histology needed in a mixed carcinoma to confer a poor 
prognosis is unclear; some investigators believe that any amount of poor-prognosis 
histology (uterine papillary serous carcinoma or clear-cell carcinoma) is sufficient, 
whereas others think that a small focus of poor histology has very little decisive 
prognostic impact. 66 The 2010 “Dataset for histological reporting of endometrial 
cancer” of the Royal College of Pathologist recommends to report any proportion of co-
existing morphological subtype and stating the approximate percentage even if it 
comprises less than 10% of the tumour tissue. This is important since the clinical 
relevance according to the proportion of histological subtype in view of tumour 
behaviour is so far controversial.67  
Treatment approaches for tumours of mixed histology, when a known aggressive 
variant is present, are similar to those for uterine papillary serous carcinoma and clear-
cell carcinoma. Adenosquamous uterine carcinoma and adenoacanthoma are also 
regarded as being of mixed histology. They are believed to be of poor prognosis. 
However, according to a large study by Pekin et al. they all have a similar prognosis, 
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suggesting that adenocarcinomas with and without squamous differentiation should be 
approached in a similar way. The prognosis is dependent on the grade of the glandular 
component. 68  
 
1.5.3 Summary of Type II endometrial carcinoma 
Although type II carcinomas only account for 10-20% of all endometrial malignancies, 
they are responsible for ~50% of all relapses and a low 5-year, all stage, overall survival 
rate of 35%.58 Clinically, type II endometrial carcinomas have an aggressive behaviour, 
with a high frequency of distant spread to pelvic lymph nodes. In the absence of an 
accepted precursor lesion there is no option to diagnose and treat a certain number of 
cases before the carcinoma has developed.  
As it will be outlined below surgical as well as systemic treatment options have so far 
demonstrated limited impact on the poor prognosis of this group of tumours. 
Additionally only few markers are available to clearly identify such lesions. A central 
aim of this study was to identify prognostic markers that can help guide treatment 
decisions in type 2 tumours.  
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1.6 Management of endometrial carcinoma 
 
1.6.1 Presentation and Diagnosis 
90% of of the women who develop endometrial cancer present with bleeding and more 
than 70% of these are postmenopausal.15 5%-15% of postmenopausal women with 
abnormal bleeding will have endometrial carcinoma. This obvious symptom encourages 
many women relatively soon after onset of these symptoms to seek medical help.69 Thus 
approximately 75% of all patients with endometrial cancer present with early stage 
disease confined to the body of the uterus. Other symptoms can include low pelvic pain, 
vaginal discharge or, in advanced cases, urinary or rectal symptoms. Not uncommonly, 
diagnosis is made following investigations after endometrial dysplastic cells were found 
in a cervical smear. Distant metastatic disease is unusual at diagnosis although local 
metastases to the lower vagina can lead to a patient presenting with vulvo-vaginal 
soreness or bleeding. In the United Kingdom and most other developed countries 
patients will be referred to a gynaecological department or a gynaecological cancer unit 
where they will undergo detailed investigation. 
The diagnostic workup usually includes clinical examination, ultrasound imaging and 
hysteroscopy/endometrial biopsy. Whilst transvaginal ultrasound has a sensitivity of 
>90% to detect endometrial abnormality it is non-specific.69 70 In the UK, women 
presenting with postmenopausal bleeding plus showing an endometrial thickness of >5 
are recommended to undergo further investigations such as hysteroscopy/endometrial 
biopsy. However, more recent guidelines such as the one from the Scottish 
Intercollegiate Guidelines Network (SIGN) recommend a cut-off threshold of 3mm.71 
 23 
 
The office based Pipelle biopsy to obtain tissue for histology is also a reliable tool with 
a reported sensitivity to detect endometrial cancer of over 95 %.72 73 
 
1.6.2 Staging 
Endometrial cancer is graded and staged on the hysterectomy specimen according to 
FIGO (International Federation of Gynaecology and Obstetrics) rules. Although the 
FIGO staging has been updated in 2009, the older staging described below will 
obviously still be found in the literature.2 
The main difference is that the old FIGO staging system divided stage I into three rather 
than two sub-stages: Stage IA, tumour limited to endometrium; IB, tumour invades up 
to less than half of myometrium; IC, tumour invades to more than one half of 
myometrium.74 In this study patients were staged within the old system since diagnosis 
and treatment predated the introduction of the new system. Table 1.3 (see page 24) 
outlines the new staging system in detail.74  
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Table 1.3  
FIGO 
STAGES  
 TNM 
CATEGORIES 
 Primary tumour cannot be assessed  TX 
 No evidence of primary tumour  T0 
0 Carcinoma in situ (pre-invasive carcinoma)  Tis 
I∗ Tumour confined to the corpus uteri  T1 
IA∗ No or less than half of the endometrium  T1a 
IB∗ Invasion equal to or more than half of the myometrium T1b 
II∗ Tumour invades cervix but does not extend beyond uterus∗∗ T2 
III∗ Local and/or regional spread as specified in IIIA, B, C  T3 and/or N1 
IIIA∗ Tumour involves serosa and/or adnexae (direct extension or 
metastasis) and/or cancer cells in ascites or peritoneal washings) # 
T3a 
IIIB∗ Vaginal involvement (direct extension or metastasis)# T3b 
IIIC∗ Metastasis to pelvic and/or para-aortic lymph nodes# N1 
IIIC1∗ Positive pelvic nodes  
IIIC2∗ Positive para-aortic lymph nodes with or without positive pelvic lymph 
nodes 
 
IV∗ Tumour invades bladder and/or bowel mucosa, and/or distant 
metastases 
 
IVA∗ Tumour invades bladder- and/or bowel mucosa  T4 
IVB∗ Distant metastasis (excluding metastasis to vagina, pelvic serosa, or 
adnexa, including metastasis to intra-abdominal lymph nodes other 
than para-aortic and/or inguinal nodes)  
M1 
 
2009 FIGO staging system for endometrial carcinoma. ∗, either G1, G2, or G3; ∗∗, 
endocervical glandular involvement only should be considered as stage I and no 
longer as stage II; #, positive cytology has to be reported separately without 
changing the stage. 
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1.6.3 Grading 
The histopathological degree of tumour differentiation (grading) has an important 
impact on the natural history of this disease and on treatment selection. Before the grade 
is determined all tumours are to be microscopically verified and classified as outlined in 
Table 1.1 on page 8. Endometrioid carcinomas are then graded into: 
 
• Gx – Grade cannot be assessed; 
• G1 – Well differentiated; 
• G2 – Moderately differentiated; 
• G3 – Poorly or undifferentiated. 
 
According to the system of the International Federation of Gynecology and Obstetrics 
(FIGO), an endometrioid carcinoma of grade 1 consists of well-formed glands, with no 
more than 5% solid non-squamous areas. Squamous differentiation is not regarded as 
solid tumour growth. Grade 2 carcinomas consist of 6–50% and those of grade 3 of 
more than 50% solid non-squamous areas.75 Conspicuous cytological and nuclear atypia 
will upgrade a tumour from grade 1 to 2, or from grade 2 to 3.  
It is important to note that according to FIGO, only endometrioid carcinomas are 
grouped with regard to the degree of differentiation. All other cases of carcinoma of 
endometrial cancers such as the typical type II cancers, UPSC, CC and tumours of 
mixed histology, are regarded as grade 3 (G3). Sarcoma and carcinosarcoma are staged 
and graded separately. 
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1.6.4 Treatment of endometrial carcinoma (type I and type II) 
1.6.4.1 Type I endometrial carcinoma 
1.6.4.1.1 Surgery  
Early stage endometrioid endometrial carcinomas (type I) which reveal localised disease 
are usually curable and treated with the removal of the uterus and ovaries with 
peritoneal washings. This achieves excellent local control of disease. The International 
Federation of Gynecology and Obstetrics (FIGO) mandates a pelvic and para-aortic 
lymphadenectomy for endometrial cancer staging, however, two recently published 
large randomized controlled trials found no survival benefit in routine pelvic 
lymphadenectomy in endometrioid endometrial cancer.76 77 Internationally and even 
within the UK there is considerable variation in the practice and extent of 
lymphadenectomy in endometrial cancer.  
1.6.4.1.2 Adjuvant therapy in type I endometrial carcinoma 
Most women with early-stage EEC recur in the vagina or pelvis. In type I endometrial 
cancer, adjuvant therapy is increasingly focused locally or even deferred depending on 
risk factors. The recently published PORTEC II trial comparing vaginal brachytherapy 
(VBT) versus pelvic external beam radiotherapy (EBRT) in prevention of vaginal 
recurrence in an intermediate risk cohort of 427 patients did not show any difference in 
disease free survival or overall survival but proved that VBT is equally effective as 
EBRT with fewer gastrointestinal toxic effects.78  
In type I endometrial carcinoma cytotoxic chemotherapy has a limited place in the 
management of advanced or recurrent endometrial cancer. Whilst no one drug or 
regimen offers a clear benefit for women with advanced endometrial cancer, platinum 
drugs, anthracyclines and paclitaxel seem the most promising agents.79 
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1.6.4.1.3 Hormone therapy 
In type I endometrial cancers with hormone receptor positivity hormone therapy is an 
option although patients are rarely curable and there is no standard therapy. It has also 
been used as an alternative treatment for a small subset of patients mainly with 
simultaneous regional and distant disease particularly if comorbidity excludes them 
from surgical intervention. Progestin therapy is also given when endometrial cancer 
recurs, although response rates are low.  
 
1.6.4.2 Type II endometrial carcinoma 
1.6.4.2.1 Surgery 
In type II endometrial cancer (UPSC, CC and tumours of mixed histology) the initial 
management for the majority of women is surgical exploration and comprehensive 
staging, including total abdominal hysterectomy and bilateral salpingo-oophorectomy, 
pelvic washings, lymphadenectomy and omentectomy. In addition to providing 
prognostic information, accurate identification or exclusion of metastatic disease is 
important for the individual planning of adjuvant therapy and surveillance. In many 
studies lymphadenectomy is believed to provide a therapeutic benefit in women with 
high-grade endometrioid endometrial cancer, and particular type II disease.65 
Unfortunately, the above mentioned ASTEC-trial as well as the trial by Panici at al. 
were underpowered to be able to make a valid statement about the value of 
lymphadenectomy in high-risk patients. In above trials only 4% and <1% (respectively) 
of the study population had UPSC histology and no individual analysis for this part of 
the population was performed. 
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1.6.4.2.2 Neoadjuvant chemotherapy  
Neoadjuvant chemotherapy has been described as a successful option in select cases 
who might be poor candidates for upfront surgery or where pre-treatment imaging 
might be suggestive of disseminated disease.80 81  
 
1.6.4.2.3 Risk and pattern of recurrence 
Surgical staging studies have defined the spread pattern of EEC, i.e. type I endometrial 
carcinoma.82 Pathologic findings associated with increased risk of nodal metastasis, as 
well as disease recurrence, include tumour grade, depth of myometrial invasion, positive 
peritoneal cytology, tumour within the isthmus-cervix, adnexal involvement, and 
LVSI.83 Women with type I endometrial carcinoma are commonly stratified based upon 
these features into groups at low, intermediate, and high-risk for recurrence of disease. 
Unfortunately, the typical features of type I endometrial cancer risk prediction such as 
myometrial invasion or lymphovascular space invasion, are not reliable in type II 
cancers to assess the risk of metastatic disease. Numerous investigators utilizing 
comprehensive staging have documented that the majority of women with type II 
endometrial cancer have a high risk of relapse and metastatic disease even in the 
absence of such “high-risk” pathologic features.48 83-88 Hui et al. found extrauterine 
disease in 38% of comprehensively staged women whose uterine disease was confined 
to an endometrial polyp.89 Slomovitz et al. needed to upstage 30 in 129 cases of UPSC 
from stage I to III solely due to positive lymphadenectomy findings.84  
The majority of UPSC patients relapse outside of the pelvis, often in multiple sites. 
Since type I and type II endometrial carcinoma show such different patterns and 
frequency of disease, there is a need for different adjuvant management plans.  
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1.6.4.2.4 Adjuvant Therapy in type II endometrial carcinoma 
Type II endometrial cancer, in particular UPSC and CC have the tendency to recur 
within the peritoneal cavity, hence most investigations into the role of radiotherapy for 
early-stage adjuvant treatment for these cancers focus on whole abdominal radiotherapy 
with or without a pelvic boost (WAPI).90-93 Above mentioned PORTEC II trial was 
underpowered to make any statement about the value of VBT or EBRT in high risk 
cases such as G3 EEC. UPSC/CC were not included. There have been studies 
comparing adjuvant radiotherapy with or without combination with chemotherapy but 
none have produced encouraging findings to support a major role for radiotherapy in the 
treatment of type II endometrial cancer.93 
Optimum treatment for type II endometrial is unclear, particularly in early disease. 
Unfortunately, there have been no randomized trials exploring the potential utility of 
adjuvant chemotherapy for women with stage I UPSC/CC. While five-year survival in a 
single institution series of 27 women with surgical stage I UPSC was reported to be 
62.9% overall, the prognosis of women confirmed to have stage IA disease appeared to 
be relatively favourable.84 There were even a number of studies advocating observation 
only in stage IA disease.55 94 95 Other groups, however, reported significant and rapid 
recurrence even in stage IA UPSC disease whether chemotherapy was given or not.96 
The high frequency of distant recurrence in early stage UPSC, along with treatment 
failures within the radiation fields, has led to increasing use of adjuvant chemotherapy 
and reports of its success. Fader et al. investigated retrospectively 141 patients and 
showed that recurrence and survival outcomes were significantly improved in patients 
who received platinum/taxane chemotherapy ± radiotherapy compared to women who 
received no adjuvant therapy or radiotherapy alone.96 Women treated with 
platinum/taxane-based chemotherapy had a significantly lower recurrence rate (11.2%) 
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when compared to patients who did not receive chemotherapy (26.9%; p = 0.021). This 
effect was most pronounced in women with stage IB/IC UPSC. Also, the use of 
intraperitoneal chemotherapy has been reported for UPSC. Chambers et al. treated 13 
women with UPSC of stage IA–IVB with intraperitoneal cisplatin along with 
intravenous doxorubicin and cyclophosphamide. The 3-year overall survival of 24.1% 
was similar to women treated at the same institution with intravenous 
cyclophosphamide, doxorubicin, and cisplatin.97 
Patients with type II endometrial cancer frequently relapse. Treatment options at 
advanced or recurrent disease are limited and consist of palliative chemotherapy with 
platinum agents or taxanes.  
The Gynecologic Oncology Group (GOG) conducted a series of phase III randomized 
prospective trials of chemotherapy for advanced-stage or recurrent endometrial 
carcinoma.98-101 The current “gold standard” treatment of advanced-stage or recurrent 
endometrial carcinoma is based upon the results of these trials. In the most recently 
completed GOG studies, the addition of paclitaxel to cisplatin and doxorubicin (TAP) 
following surgery (cytoreduction to less than 2 cm maximal residual disease) and 
radiation (tumour volume directed) was not associated with significant improvement in 
recurrence-free survival but was associated with greater toxicity in women with 
advanced stage endometrial cancer.102 The GOG concluded that despite the apparent 
biological differences between endometrioid and serous endometrial cancers, the overall 
response rates (40-50%) to taxane, doxorubicin and platinum chemotherapy and 
survival after such treatment is similarly poor for women with advanced or recurrent 
UPSC as for those with advanced or recurrent endometrial cancer of other histologies. 
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1.6.4.2.5 Hormone Therapy 
In cases of type II endometrial carcinoma progesterone treatment has no effective role. 
 
1.6.4.2.6 Summary of treatment of type II endometrial cancer 
Although type II endometrial cancer comprises of 10-15% of all endometrial carcinoma 
cases, it accounts for a disproportionately high number of endometrial cancer related 
deaths. Whilst type I endometrial carcinoma is usually diagnosed at an early stage, is 
often curable and long term survival favourable, type II cancers often present already 
with extra-uterine disease which sometimes can only be identified with comprehensive 
surgical staging. Despite improvements in surgery such as cytoreduction and 
lymphadenectomy the incidence of both local and distant recurrence is high among 
women with stage I UPSC/CC compared to most women with EEC. 
In type II endometrial cancer adjuvant platinum/taxane-based chemotherapy with or 
without radiotherapy appears to improve progression-free and overall survival outcomes 
only in the comparatively rare early-stage patients. Traditional therapies are not 
associated with long-term survival in women with more advanced or recurrent disease. 
Whatever the receptor status might be, hormone therapy seems to have no role in type II 
endometrial carcinoma. 
Altogether, treatment options in type II endometrial cancers are largely limited to 
aggressive surgical- and/or chemotherapy regimen, which have not altered the poor 
prognosis of these tumours. There is an unmet clinical need for robust prognostic 
markers that can help guiding therapeutic decisions in these endometrial cancer tumour 
types, particularly at recurrence and in advanced stage tumours and to identify new 
therapeutic targets.  
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1.7 Uterine sarcoma 
 
Uterine sarcomas arise from mesenchymal tissue (e.g. connective tissue, smooth 
muscle) and account for 3 - 7% of uterine malignancies. They are rare, occur at a mean 
age of 60, behave generally more aggressively and show a poorer prognosis than 
endometrioid endometrial cancers with a 5-year survival rate of ca 40%.103 Table 1.4 
(see below) lists the most common types of histology in uterine sarcomas.  
 
Table 1.4 
 CLASSIFICATION OF SARCOMA   
1. Carcinosarcoma or MMMT   (40-50%) 
2. Leiomyosarcoma  (30-40%) 
3. Endometrial stromal sarcoma (ESS)  (10-15%) 
4. Adenosarcoma  (<10%) 
5. Undifferentiated endometrial sarcoma  (5%) 
6. Smooth-muscle tumours of uncertain malignant potential           
(STUMP) 
rare 
 
WHO classification of the most common types of uterine sarcoma, (%) = 
percentage among sarcoma group. 
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“Typical” sarcoma types are the leiomyosarcoma, endometrial stromal sarcoma (ESS) 
and undifferentiated endometrial sarcoma and are described together. There were no 
cases of STUMP and adenosarcoma in the cohort of this study, thus they are not 
described further. For reasons indicated in chapter 1.2 carcinosarcoma is described in 
chapter 1.8. 
 
1.7.1 Presentation and diagnosis of sarcomas 
Some sarcomas present with vaginal bleeding with or without odorous discharge and 
may be accompanied with abdominal distension or pelvic pressure symptoms (urinary 
frequency, constipation etc.) and pain. Leiomyoma and leiomyosarcoma are difficult to 
distinguish but if they are symptomatic in a postmenopausal state or with 
disproportional vaginal bleeding the suspicion should be raised. Only exceedingly rarely 
does a leiomyoma degenerate into a sarcoma. The diagnosis of uterine sarcoma is based 
on histological examination of the believed myomatous tissue or the uterine specimen. 
Uterine curettings alone are not reliable. 
 
1.7.2 Staging of sarcomas 
Table 1.5 (see page 34) shows the FIGO staging system for uterine sarcoma (2009).1  
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Table 1.5 
STAGE DEFINITION 
 
 (1.) Leiomyosarcoma and Endometrial Stromal Sarcoma (ESS) 
I Tumour limited to uterus 
        IA Less than or equal to 5 cm 
        IB More than 5 cm 
II Tumour extends beyond the uterus, within the pelvis 
        IIA Adnexal involvement 
        IIB Involvement of other pelvic tissues 
III Tumor invades abdominal tissues (not just protruding into the abdomen) 
        IIIA One site 
        IIIB More than one site 
        IIIC Metastasis to pelvic and/or para-aortic lymph nodes 
IV  
        IVA Tumour invades bladder and/or rectum 
       IVB Distant metastases 
  
 (2) Adenosarcomas 
I Tumour limited to uterus 
        IA Tumour limited to endometrium/endocervix with no myometrial invasion 
        IB Less than or equal to half myometrial invasion 
        IC More than half myometrial invasion 
II Tumour extends beyond the uterus, within the pelvis 
        IIA Adnexal involvement 
        IIB Tumour extends to extrauterine pelvic tissue 
III Tumour invades abdominal tissues (not just protruding into the abdomen). 
        IIIA One site 
        IIIB More than one site 
        IIIC Metastasis to pelvic and/or para-aortic lymph nodes 
IV  
        IVA Tumour invades bladder and/or rectum 
       IVB Distant metastasis 
  
 (3) Carcinosarcomas 
 Carcinosarcomas should be staged as carcinomas of the endometrium. 
FIGO staging system for uterine sarcoma (2009) 1 
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1.7.3 Management of sarcomas 
Total abdominal or laparoscopic hysterectomy (TAH/TLH) and bilateral salpingo-
oophorectomy (BSO) is the standard surgical treatment and staging. Radical surgery is 
of no benefit. Peritoneal washings and biopsies from areas of suspected metastases are 
part of the staging. Cytoreduction in case of tumour spread outside the pelvis has not 
been proven beneficial. Routine pelvic and or para-aortic lymphadenectomy is not 
required in leimoyosarcoma and undifferentiated sarcoma. This has been suggested for 
ESS but it is still under investigation. Obviously, visibly enlarged nodes may be 
biopsied. Preservation of the ovaries only in young women may be safe in early-stage 
leiomyosarcoma whilst it is uncertain in ESS and undifferentiated sarcomas.  
As to adjuvant therapy, radiotherapy (RT) has demonstrated a reduction in local 
recurrence (LR) and improvement in progression-free survival (PFS) in uterine sarcoma 
but the overall survival (OS) benefit is unclear. Adjuvant chemotherapy is commonly 
recommended for women with resected stage I to IVa disease, particularly those at high-
risk for recurrence. 
1.7.3.1 Endometrial stromal sarcoma (ESS) 
Hormonal therapy is the mainstay of adjuvant therapy and associated with improved 
overall survival for oestrogen and progesterone receptor-positive ESS although agents 
and regimen vary. Hormone therapy may also be used in other ER/PR-positive uterine 
sarcomas. Commonly, GnRH-analogues are prescribed for pre-menopausal women and 
aromatase inhibitors (exemestane, anastrozole, letrozole) or progestins (e.g. 
medroxyprogesterone acetate (MPA) or megestrol acetate) for post-menopausal women. 
There is some suspicion that tamoxifen might be associated with tumour recurrence. 
Aromatase inhibitors may have therapeutic value. Adjuvant radiotherapy may not be 
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indicated for a tumour with such good prognosis in early disease but may be used in 
advanced stage to control local disease.  
1.7.3.2 Leiomyosarcoma 
Regarding adjuvant chemotherapy, the combination of doxorubicin or docetaxel / 
gemcitabine is currently a recommended regimen which showed some survival benefit 
in a small prospective trial.104 The benefit of radiotherapy (RT) has not been reliably 
proven, possibly due to its tendency for distant metastases. It may be used in situations 
of local recurrence or the assumed risk for it. Some patients may respond to hormonal 
therapy. 
1.7.3.3 Undifferentiated sarcoma 
It is suggested to apply adjuvant RT for patients with a high risk of local recurrence. 
There is no consensus about adjuvant chemotherapy for undifferentiated endometrial 
sarcoma. A platinum based combination chemotherapy might be a reasonable option. 
 
1.7.4 Prognosis of sarcomas 
Uterine sarcomas as a whole carry a significantly poorer prognosis as compared to other 
gynaecologic malignancies. In stage I uterine sarcomas have a five-year survival rate of 
76 %, falling to 60, 45, and 29 % for stages II, III and IV. Tumour stage, degree of 
resection, grading, and mitotic count are believed to correlate with prognosis. 
Postmenopausal women are said to do worse than pre-menopausal women. ESS as an 
exception is believed to have a fairly good prognosis whilst leiomyosarcomas have a 
worse prognosis relative to other uterine sarcomas.  
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1.7.5 Summary of uterine sarcoma 
Sarcomas are as a group of uterine malignancies, with the exception of the STUMP, of 
particularly poor prognosis. Their histologic and prognostic diversity as well as relative 
rarity, render large trials to optimize diagnosis, prognosis or treatment difficult to 
conduct. New molecular markers may open new ways to individualise prognosis and 
possibly improve treatment. 
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1.8 Carcinosarcoma 
 
Malignant mixed mullerian tumour = MMMT. Uterine carcinosarcoma are a biphasic 
neoplasm distinctly and separately composed of both carcinomatous (epithelial) and 
sarcomatous (connective tissue, i.e. stromal) elements. It comprises of only 1% of 
uterine neoplasms but accounts for 40% of all sarcomas.105 
 
1.8.1 Presentation and diagnosis of carcinosarcomas 
Carcinosarcoma is a rare and aggressive tumour with 30% of women showing extra-
uterine disease by the time of diagnosis. It is diagnosed at a median age of 65 years. The 
serum level of CA125 is usually elevated. It carries a similar risk profile when 
compared to endometrial cancer: obesity, nulliparity, exposure to oestrogen and history 
of tamoxifen use.106  
Patients often present with vaginal bleeding and a polypoid mass filling the endometrial 
cavity. Both histological components may display different histologies. The epithelial 
component may be an endometrioid, serous, clear cell adenocarcinoma; squamous or 
undifferentiated. The stromal component may be of uterine origin (endometrial, 
leimyosarcoma or undifferentiated) - these tumours are termed homologous. If the 
stromal component is of any other connective tissue (chondrosarcoma, osteosarcoma, 
etc.) it is termed a heterologous tumour. The most common form consists of a high-
grade serous papillary carcinoma and an endometrial stromal sarcoma. In metastatic 
sites the epithelial component seems to play the dominant role, hence metastatic 
carcinosarcoma often display a clinical behaviour similar to uterine papillary serous cell 
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carcinoma or epithelial ovarian carcinoma.107 The diagnosis is made at histology and 
often only after hysterectomy. Approximately 40% of endometrial biopsies will not 
reveal the correct diagnosis. 
 
1.8.2 Staging of carcinosarcoma 
Carcinosarcoma is staged according to the FIGO staging system for endometrial 
carcinoma. See Table 1.3 on page 24. 
 
1.8.3 Management of carcinosarcoma 
TAH and BSO with peritoneal washings is the standard of care. Some clinicians will 
advocate an omentectomy due to the risk of upper abdominal disease. The incidence of 
regional lymph node metastases is approximately 20%. Pelvic and para-aortic 
lymphadenectomy will complete the staging procedure and seems to carry a significant 
survival benefit.107 
The recurrence rate is approximately 60%. The role of adjuvant chemo- and 
radiotherapy is uncertain. Whilst brachytherapy or external beam radiotherapy seems to 
benefit local control it may not improve disease-free survival or overall survival. 
Adjuvant chemotherapy has yet to prove its effectiveness. The approach is like that for 
high grade endometrial carcinomas. Cisplatin, ifosfamide, doxirubicine and taxanes are 
often mentioned choices of agents with various combinations.108 109 In view of the poor 
prognosis even with early stage disease, sequential or multimodality therapy regimens 
have been introduced including chemotherapy and pelvic as well as whole body 
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radiotherapy. Favourable results have been reported anecdotally. However, there are no 
randomized trials available. 
 
1.8.4 Prognosis and summary of carcinosarcoma 
Carcinosarcoma are the smallest group of uterine malignancies and like sarcoma of 
particularly poor prognosis. The overall 5-year survival for patients with 
carcinosarcoma is reported to be 25 - 35% and for those with stage I (confined to the 
corpus) ca 50%.105 109 This is in contrast with that of endometrial cancers for which 5-
year survival in stage I disease is approximately 80% or better.110-112 Recurrences tend 
to occur within the first year following treatment. Their general rarity as well as their 
vast diversity of biphasic histological composition, render clinical trials difficult to 
conduct but studies which include carcinosarcoma are necessary on the quest to find 
potential prognostic and/or therapeutic markers to improve outcome. New molecular 
markers may open new ways to individualise prognosis and possibly improve treatment. 
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1.9 Translational research and endometrial      
carcinoma 
 
In this chapter translational research will be defined, molecular markers which are 
characteristic of type I and II endometrial cancer will be outlined and novel markers 
currently investigated in trials highlighted in chapter 1.10. Chapter 1.11 will then 
introduce the novel markers that were investigated in this study. 
 
1.9.1 Definition 
The Translational Research Working Group of the American National Cancer Institute 
defines: "Translational research transforms scientific discoveries arising from 
laboratory, clinical, or population studies into clinical applications to reduce cancer 
incidence, morbidity, and mortality."113 One role of translational medicine is to provide 
biomarkers which enhance decision making at critical milestones in the development or 
treatment process of a disease. A biomarker is a quantifiable biological variable that 
characterises cellular, organ, physiological, pathological or clinical condition. For 
example a biomarker could be (amongst others) a gene or protein expression or 
biochemical profile or a quantifiable measurement from an image. 
 
1.9.2 Rationale for molecular medicine and novel therapies 
in endometrial cancer 
Current understanding is that the ‘umbrella-diagnosis’ of endometrial cancer 
encompasses a heterogeneous disease with grossly different biology and therefore 
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oncologic behaviour, which demands more individualised treatment. Endometrial 
carcinoma develops as the result of an accumulation of alterations in cellular regulatory 
pathways, such as oncogene activation and tumour suppressor gene inactivation which 
leads to dysfunctional cell growth. Some of these molecular alterations appear to be 
more specific in type I, some in type II endometrial cancers.114 
Advanced understanding of the molecular mechanisms in cancer development, 
progression and metastasis has unveiled a spectrum of targets for a more precise 
understanding and definition of the diseases in question (type I and II endometrial 
cancer), i.e. a “molecular profile” and the subsequent therapeutic intervention.115 
Table 1.5 (see page 34) will outline a summary of markers which are currently used to 
distinguish between type I and type II endometrial cancers. It is recommended to use a 
panel of markers for that purpose for none of these markers are sufficiently sensitive or 
specific enough to function alone in a binary way. Chapter 1.9.3 will outline these 
markers in more detail. 
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Table 1.6 
MARKER TYPE I 
ENDOMETRIOID 
CARCINOMA 
TYPE II 
NON-ENDOMETRIOID 
CARCINOMA 
ER/PR expression Frequent 
(60-95%)116 117-119 
Less frequent? 
(9-54%)120 
pTEN mutation  
Inactivation (loss) 
Frequent 
(-90%)121 122 
Rare/Less frequent  
(-10%) 38 123 
P16 mutation 
Inactivation 
Less frequent 
(10%) 38 
Frequent 
(40%) 38 
P53 mutation 
overexpression 
Less frequent 
(10-20%) 38 
Frequent 
(70-90%) 38 45 123 124 
K-ras mutation Partially 
(10-30%)32 35 
Rare/less frequent 
(0-8%) 35 38 125 126 52 
Erb B2 amplification 
(Her2-neu overexpression) 
Rare 
(2-5%)38 
Frequent 
(26%)38 
PIK3CA mutation 
overexpression 
Frequent 
(30%)127 
(Less) frequent? 
(5-27%)45 52 127 
Microsatellite Instability 
(MSI) 
Frequent 
(10-40%) 38 128 
Rare 
(0-5%) 38 129 130 
β-Catenin (CTNNB1)  
overexpression 
Frequent 
(25-40%)38 
Rare 
(0-5%) 38 53 
E-Cadherin  
overexpression 
Less frequent 
(10-20%)38 
Frequent 
(80-90%)38 
PPP 2R1A mutation  
Inactivation (loss) 
Less frequent 
 (7%)52 
Frequent 
(ca 40%)52 
ARID 1A mutation  
(loss of protein BAF250a) 
Frequent 
(20-47%)52 131  
Less frequent? 
(0-11%)52 131 
Molecular features of endometrial carcinoma type I and II. ER/PR = oestrogen 
receptor/progesterone receptor; pTEN = Phosphatase and tensin homolog; p16 = Cyclin-dependent 
kinase inhibitor 2A; P53 = Tumour protein 53; K-ras = GTPase encoded by the KRAS gene; Erb 
B2 = HER2 (Human Epidermal Growth Factor Receptor 2); PIK3CA = Phosphatidylinositol 3'-
kinase catalytic subunit; PPP2R1A= subunit of protein phosphatase 2; ARID 1A = AT-rich 
interactive domain-containing protein 1A.  
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1.9.3 Molecular characteristics of type I endometrial 
carcinoma 
1.9.3.1 Roles of oestrogen and progestins  
Type I endometrial carcinoma are oestrogen receptor (ER) and progesterone receptor 
(PR) positive in 60-95% of cases.116 117-119 
Oestrogen and progestins have largely reciprocally opposing roles on hormonally 
responsive endometrial tissue. Progestins exert a direct effect on co-existing oestrogenic 
action by down-regulating the oestrogen receptor (ER). For this reason, the combined 
biologic effects of circulating progestins and oestrogens are dominated by the 
progestational component Large-scale profiling of endometrial tissue RNAs have 
demonstrated that type 1 endometrioid carcinoma mirrors the protein expression profile 
seen in oestrogen-driven proliferative endometrium and lacks expression of those genes 
induced by progestins. A number of genes are not or underexpresssed amongst which 
are tumour-suppressor genes affected by primary mutation or deletion. Downstream 
target genes are also affected. Another concept is oestrogenic promotion of cell 
proliferation and inhibition of apoptosis with concomitant modulation of tumour 
suppressor function. Whilst endometrial cell-proliferation is promoted so is PTEN 
expression to regulate mitosis and apoptosis. However, in the absence of PTEN-
opposing progestins not only normal but also mutant forms of PTEN are greatly 
increased which consecutively stop counterbalancing proliferation thus promote tumour 
development.132 133 
Oestrogen also has a very interesting role in mediating increased cancer risk via down-
regulating ‘cables’, a cyclin-dependent kinase binding protein. In normal endometrial 
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tissue cables is upregulated and kept in balance by progesterone, effectively slowing 
down cell proliferation. In the majority of endometrial cancers however, cables is 
absent, possibly downregulated during tumourigenesis by unopposed oestrogen. In 
support of this theory it has been demonstrated that mutant mice deficient in cables 
develop hyperplasia and cancer in early age.134 Whilst it is known that progesterone 
plays a key role in counter-balancing the proliferative role of oestrogen and its absence 
results in endometrial hyperplasia and endometrial cancer, its precise actions are 
complex and not fully understood. Like oestrogen, progesterone acts on its specific 
receptor. Progesteron receptors (PR) with its isoforms PR-A and PR-B are present in 
both endometrial stroma and epithelium but their expression status fluctuates according 
to the hormonal status and other factors. 
In type I endometrial cancers ER and PR status are characteristically positive which is 
indicative of a less aggressive tumour and predictive of a favourable response to 
progestin therapy. 
 
1.9.3.2 Microsatellite instability 
Microsatellites are short segments of repetitive DNA bases found throughout the 
genome and mostly in non-coding DNA. During replication DNA repair errors take 
place leading to small alterations in these short segments or microsatellites. The 
progressive accumulation of these alterations at microsatellite loci is called 
microsatellite instability (MSI). If MSI occurs in important regulatory genes it may 
promote carcinogenesis and is known to play an important role in sporadic colon 
cancers and in several non-colonic tumours. Patients with known MSI, also called 
Lynch-Syndrome are believed to have in addition to colon-cancer risk a lifetime risk for 
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endometrial cancer between 40 and 60% corresponding to a relative risk of 13–20%.135 
MSI is found in 17–25% of sporadic type I endometrial carcinoma128, but is rarely 
present in type II tumours.129 130 
 
1.9.3.3 PTEN – tumour suppressor gene 
PTEN (phosphatase and tensin homolog deleted on chromosome 10) is a protein which 
in humans is encoded by the PTEN gene.136 PTEN acts as a tumour suppressor gene 
through the action of its phosphatase protein product. It removes phosphate groups from 
key phosphoinositide signalling molecules, thus inhibiting AKT and its downstream 
signalling product mTOR.137 Decreased activity or loss-of-function mutations of PTEN 
lead to the activation of multiple signalling pathways, including the PI3K/Akt/mTOR 
pathway, which affects cell proliferation, apoptosis and migration.121 122 
Mutations of PTEN have been found in several other tumours such as prostate cancer 
and glioblastoma. Up to 80% of cases of endometrioid carcinoma reveal a loss of PTEN 
expression, mainly due to mutations, and to a lesser extent to a loss of heterozygosity 
(LOH).121 122 Mutations of PTEN have also been described in endometrial hyperplasia 
with and without atypia.27 29 Given the role of endometrial hyperplasia as the putative 
precursor of type I tumours, PTEN mutations are presumed to play an early role, 
although probably not a determining step, in tumourigenesis.  
 
1.9.3.4 β-Catenin (CTNNB1) 
The CTNNB1 gene is located on chromosome 3p21 and encodes the 88 kDa protein β-
catenin. Alpha (α), beta (β), and gamma (γ) catenins belong to a family of structurally 
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related cytoplasmatic proteins according to their electrophoretic mobility. β-catenin 
appears to be important in the functional activities of both APC (adenomatous polyposis 
coli) and E-cadherin. It is a component of the E-cadherin-catenin unit, essential for cell 
differentiation and maintenance of normal tissue architecture and also plays an 
important role in Wnt signal transduction pathway. Mutations of CTNNB1 result in 
stabilisation of a protein that resists degradation, leading to nuclear accumulation of β-
catenin. This can be demonstrated by immunostaining and has been described in 
endometrioid endometrial carcinoma. A number of studies have analysed endometrial 
carcinomas showing that nuclear accumulation of β-catenin is significantly more 
common in endometrioid lesions (31– 47%) compared with non-endometrioid histology 
(0–3%).53 
 
1.9.3.5 K-ras 
K-ras encodes a small cytoplasmatic, cellular membrane GTPase, which functions as a 
molecular switch during cell signalling and which is largely related to tumour growth 
and differentiation. K-ras mutations have been identified in 10–30% of endometrioid 
endometrial carcinomas but seem to be almost completely absent in serous and clear 
cell carcinomas of the endometrium.35 38 125 126 Lagarda et al. and others described to 
have found more K-ras mutations in MSI-positive carcinomas than in MSI-negative 
tumours. A possible explanation could be a simultaneous occurance prior to clonal 
expansion.34 138 Endometrial hyperplasia cases and endometrioid endometrial 
carcinomas were observed to have similar rates of K-ras mutations. This might indicate 
an early occurrence in endometrial carcinoma development.139 No relationship has been 
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found between K-ras mutations and tumour stage, histologic grade, depth of myometrial 
invasion, age or clinical outcome in endometrioid endometrial carcinomas.36 
 
1.9.3.6 PIK3CA 
PIK3CA (Phosphatidylinositol 3-kinase, catalytic, alpha polypeptide) gene locates on 
chromosome 3q26.32. Phosphatidylinositol-3-kinase (PI3K) is heterodimeric lipid 
kinase consisting of a catalytic subunit (p110) and a regulatory subunit (p85) in the 
PI3K/AKT signalling pathway. Mutations in PIK3CA, which codes for the p110a 
catalytic subunit of PI3K, have been described in various tumours and may contribute to 
the alteration of the PI3K/AKT signalling pathway in type I endometrial carcinoma.140-
142
 Oda et al. described mutations in PIK3CA gene in endometrial carcinomas for the 
first time. In their series PIK3CA mutations occurred in 36% of the cases, and coexisted 
frequently with PTEN (15–27%)35 143 and K-ras mutations36 suggesting that the 
PIK3CA mutations cooperate with these alterations in malignant transformation.144 
PIK3CA mutations did not correlate with MSI or β-catenin/CTNNB1 mutations.145 
Subsequent studies have shown that PIK3CA mutations are frequent in endometrioid 
endometrial carcinoma, in association with invasion, and adverse prognostic factors 
such as blood vessel invasion.142 A number of publications list PIK3CA mutations as a 
characteristic feature of type I endometrial carcinoma found with a frequency of ca. 
30% in contrast to only 5% of type II.127 However, Hayes et al. found mutations of 
PIK3CA in 15% and Kuhn et al. in 23,7% of papillary serous carcinoma.45 146 In fact 
Konstantinova et al. demonstrated PIK3CA mutations with a high frequency in 
metastatic tumours and in 50% of samples displaying serous differentiation, serous and 
mixed endometrioid/serous tumours.147 Kuhn et al are among the most recent 
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publications to regard the genetic aberrations involving the PI3K pathway as a major 
mechanisms in the development of uterine serous carcinoma.45  
This discrepancy of findings elucidates the early days and difficulty of interpretation of 
molecular research – in the above case one of the confounding factor is surely the 
unclear pathologic and molecular differentiation of endometrioid and non-endometrioid 
tumours. 
 
1.9.4 Molecular characteristics of type II endometrial 
carcinoma 
1.9.4.1 p53 
p53 is a tumour suppressor gene located on the short arm of chromosome 17. Wild type 
p53 protein contributes to tumour suppression through both arrest of cell proliferation 
and induction of cell death through apoptosis.148 149 Inactivation of p53 function through 
allelic loss, mutation, or complex formation with other nuclear proteins contributes to 
malignant transformation. This process makes malignant cells more resistant to 
cytotoxic chemotherapeutic drugs and radiation because of failure in induction of 
apoptosis.150 Although p53 is one of the most commonly mutated genes in human 
tumours 151 the molecular and immunohistochemical investigation of p53 expression in 
endometrial cancer is contradictory and its role remains to be defined. 
Mutations in the p53 gene are a frequent and seemingly characteristic finding in type II 
serous tumours with positive immunohistochemistry reported in 71–90% of tumours.123 
124
 
45
 They are only present in 10–20% of endometrioid endometrial carcinoma, which 
are mostly high-grade.145 P53 is regarded the most characteristic genetic alteration of 
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non-endometrioid endometrial carcinomas36 37 and may be useful in their distinction 
from endometrioid endometrial carcinomas.152 
 
1.9.4.2 Her-2/neu 
Epidermal growth factor receptor II or Her2/neu is an oncogene that codes for a 
transmembrane receptor tyrosine kinase involved in cell signalling and located at the 
long arm of chromosome 17q12.  
Endometrial carcinomas are known to sometimes overexpress and/or amplify Her2. 
Aggressive tumours of high grade or serous histology appear more likely to be Her2 
positive.153 154 However, the exact frequency of Her2 amplification/overexpression in 
type II endometrial carcinoma remains controversial. Her2 gene amplification has been 
reported to occur in 6 out of 28 (21%), 17 out of 58 (29%), or 11 out of 26 (42%) of 
patients with uterine serous papillary cancer 153 155 156, and Her2 protein overexpression 
was seen in 12 out of 68 (18%) of cases.157 In clear cell endometrial cancer Her2 
amplification has been described in two out of nine (22%) and three out of six (50%) of 
the reported cases.153 155 Overall Her2/neu overexpression or amplification appears to be 
more frequently found in non-endometrioid endometrial carcinoma (18–80%) 114 than in 
grade 2 and 3 endometrioid carcinoma (10–30%) 36 37 and has been associated with 
adverse prognostic parameters including advanced stage, high histological grade, and 
low overall survival.114 However, the wide range in reported frequency of Her-2 
expression in either type of endometrial cancer has so far rendered its usefulness as a 
clinical marker controversial. The anti-Her2 monoclonal antibody, trastuzumab, has 
improved the prognosis of women with Her2-positive breast cancer, both when used as 
part of adjuvant therapy and in the setting of metastatic disease.158 In a front-line 
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chemotherapy trial (GOG protocol #177) the Gynecologic Oncology Group (GOG) 
analyzed tumours of women with advanced or recurrent endometrial carcinoma, and 
found that 12% of tumours demonstrated Her2 gene amplification and 20% 
demonstrated strong (3+) immunohistochemical (IHC) staining for Her2. 21% of grade 
3 non-serous tumours and 21% of serous tumours were FISH positive.155  
The GOG undertook a phase II trial (GOG protocol #181B) of single agent trastuzumab 
to evaluate its potency against stage III or IV or recurrent Her2-positive (2+ or 3+ 
immunohistochemical staining) endometrial carcinoma. Of 286 tumours screened 33 
(11.5%) were Her2-amplified. 3 of 8 clear (38%) cell carcinomas and 7 of 25 serous 
carcinomas (28%) screened exhibited Her2 amplification compared with 7% (2/29) of 
endometrioid adenocarcinomas. Out of the 33 patients who enrolled in the study 18 had 
tumours with known Her2 amplification. Whilst no major tumour responses were 
observed, 12 women showed stable disease, 18 had increasing disease, and in 3 cases 
tumour response was unclear. Neither Her2 overexpression nor Her2 amplification 
appeared to be associated with progression-free survival or overall survival. The report 
concluded that trastuzumab as a single agent did not demonstrate activity against 
endometrial carcinomas with Her2 overexpression or Her2 amplification.159 So far, 
whilst Her2 has been reported to be associated with type II endometrial carcinoma, it 
has not been reliably proven to be of prognostic benefit for poor prognosis endometrial 
cancer. 
1.9.4.3 E-Cadherin 
Cadherins are a family of adhesion molecules essential for tight connection between 
cells. E-cadherin is a transmembrane protein encoded by CDH1 gene and locates on 
chromosome 16q22.1. Its extraellular domain regulates cell–cell adhesion via a Ca2+-
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dependent mechanism. Its role in inhibiting invasion and metastasis is related to its 
function in prohibiting the first step in the metastatic cascade, namely local invasion.36 
37
 In vitro analyses have correlated lost or down-regulated expression of E-cadherin in 
tumour cells with promoting tumour invasion and metastasis in murine models and 
adverse clinicopathological characteristics in numerous human cancers.160 161 
Underexpression of E-cadherin is frequent in endometrial carcinoma and may be caused 
by loss of heterozygosity (LOH) or promoter hypermethylation. LOH at 16q22.1 is seen 
in almost 60% of non-endometrioid endometrial carcinoma, but in only 22% of 
endometrioid endometrial carcinoma.38 In endometrial carcinoma, partial or complete 
loss of E-cadherin expression correlates with aggressive behaviour.36 
Kim YT et al. and Mell LK et al. investigated E-Cadherin expression in endometrial 
cancer in 33 and 102 patients with endometrial carcinoma of various stages, grades and 
histology types.162 163 Both studies showed evidence that decreased membranous E-
cadherin expression is predictive for endometrial cancer mortality, disease progression, 
and extrapelvic recurrence, independent of known prognostic factors such as stage, 
grade, and histological subtype. Both observed an inverse relationship between E-
cadherin expression and adverse outcomes. However the prognostic power for type II 
endometrial cancer has not been reliably shown. On multivariate cox regression 
analyses in the study of Mell LK et al., a higher E-cadherin expression score was 
associated with statistically significant decreases in endometrial cancer mortality (HR, 
0.23; 95% CI, 0.055– 0.94; P - 0.040), disease progression (HR, 0.28; 95% CI, 0.10–
0.77; P - 0.014), and extrapelvic recurrence (HR, 0.24; 95% CI, 0.062– 0.97; P - 0.045). 
However, whilst Kim YT et al. showed a significant correlation between aberrant E-
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cadherin and type II endometrial cancer (n =5), Mell LK et al. did not find such an 
association. 
Whilst the E-cadherin catenin complex is undoubtedly of enormous relevance for the 
formation of tight cell-cell adherence, hence cell mobility and growth and thus plays a 
significant role in tumourigenesis, these are relative downstream products in the 
signalling cascade towards cell mobility and metastasis. It would be of wider interest to 
find and influence higher organised proteins which actually manage the above complex. 
1.9.4.4 p16 
P16 plays a known role in cell cycle regulation as a tumour suppressor gene located on 
chromosome 9p21.37 P16 inactivation can lead to uncontrolled cell growth. This seems 
to be more frequent in non-endometrioid endometrial carcinoma (40–92%) than in 
endometrioid endometrial carcinoma (7-25%).37 53 120 In a population-based study of 
316 patients loss of p16 protein expression was significantly related to a subgroup of 
aggressive endometrial carcinomas and poor prognosis. Thus, absent or minimal nuclear 
staining was associated with increased age at treatment, higher FIGO stage, serous 
papillary or clear cell histological types, high histological grade, and aneuploid tumours. 
Furthermore, there were strong correlations with increased tumour cell proliferation, 
supporting the role of intact p16 protein as a cell cycle inhibitor.164  
Loss of p16 expression is also correlated with K-ras and p53 mutations and is associated 
with high stage, high grade, and poor survival. 36 
However, the importance of the cell cycle regulator p16 is still controversial, since its 
alteration varies dramatically in several studies, possibly due to the applied techniques 
and interpretation of staining.165 Also the underlying mechanism is yet unclear, because 
neither promoter hypermethylation nor deletion or mutation is frequently found.164 166 
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1.9.5 Molecular differentiation and overlapping of 
endometrioid (type I) and non-endometrioid (type II) 
endometrial carcinoma 
 
As much as Bokhman’s system of the dualistic model of endometrial cancer helped 
clinicians recognise the clinical, therapeutic and prognostic gap between type I and II 
endometrial carcinoma, its oversimplification and classification also poses a risk of 
misdiagnosing certain types of tumours which either do not fit into the defining criteria 
of type I and type II endometrial cancer or its clinico-pathological behaviour is crossing 
the dividing line between the two types.14 
On the type I side of the division it is particularly the case for grade 3 endometrioid 
carcinomas. They often take a more aggressive clinical course and have a significantly 
worse prognosis than grade 1 and 2 endometrial cancers.167 168  
On the type II side recent publications suggested that the current pathological 
classification and grading system of high-grade endometrial carcinomas is problematic 
in both reproducibility and prognostic accuracy.168 169  
Llobet et al. demonstrated main molecular alterations involved in endometrial 
carcinoma for endometrioid and non-endometrioid endometrial cancer. Whilst pTEN, 
MSI, PIK3CA and K-ras mutations are understood to be characteristic features of type I 
endometrial cancer such mutations only occur in 15-50% of cases. Conversely the same 
molecular alterations are observed in type II endometrial cancers in up to 15%. Also, 
whilst p53, E-cadherin and PPP 2R1A mutations are regarded as characteristic for type 
II endometrial carcinoma they are also detected in grade 3 endometrioid carcinomas and 
carcinosarcomas. McConnechny et al. suggest that since no single gene mutation or 
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molecular alteration seems to be sensitive and specific enough to define the risk 
grouping of these cancers it is likely that the analysis of whole gene panels will be 
needed to guide subclassification. New sequencing technologies will soon be available 
to analyse multiple genes and samples simultaneously, making large mutational studies 
achievable.52 170 
In their analysis of 152 endometrial tumour tissue samples and 260 endometrial tumour 
DNA samples McConnechy et al. postulated a ‚mutational flow’ from ‘classic’ type I, 
low grade endometrioid tumours via mixed serous and endometrioid types with mixed 
clinical aggressivenes to the very aggressive ‘classic’ uterine papillary serous carcinoma 
with a predictable mutation profile. In their mutation frequency analysis grade 3 
endometrioid cancers were in some cases (p53, PIK3CA and PPP2R1A) based between 
low grade endometrioid carcinoma (grade 1 and 2) and uterine serous carcinoma. Other 
results within the same study (pTEN, MSI) could not support the proposed theory of a 
mutational flow and concurrant clinical pictures of gradual disease development.  
However, they demonstrated that the mutation profile of grade 3 endometrioid 
carcinoma was mostly distinctly different from that of the low grade, endometrioid 
endometrial carcinoma. These results also demonstrated that more molecular markers 
are necessary to improve the sub-optimal performance of conventional histopathological 
assessment of endometrial tumours.168 
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1.10 Molecular targeting therapies 
There are a number of molecular markers which already have been investigated for their 
potential role in endometrial cancer. In addition a few agents have been developed 
trying to target these marker. A variety of agents are currently undergoing clinical 
development or are already used in trials in endometrial cancer. These agents target 
tumour cells or the tumour environment including stromal cells, endothelial cells, 
endothelial precursor cells, pericytes, and immune cells. 
In 2010/2011 about 250 clinical trials involving endometrial cancer are registered 
internationally. 59 of these included some form of targeted therapy. These studies focus 
almost exclusively on recurrent or persistent disease, none of them focus on type II 
endometrial cancer. Agents are used as monotherapy or in combination with chemo- or 
radiotherapy and also with other targeting agents. 
Most trials cover three groups of agents: Receptor tyrosine kinase (RTK) -inhibitors or -
antibodies, mammalian Target of Rapamycin (mTOR)-inhibitors and oestrogen 
inhibitors (Selective estrogen receptor modulators (SERMs), aromatase inhibitors). 
Among the RTK’s, the most widely researched molecules are the epidermal growth 
factor receptor (EGFR) family and the vascular endothelial growth factor – (VEGF) and 
- receptor (VEGFR) family including well known agents such as Bevacizumab, 
Trastuzumab and Cetuximab. None of these agents have so far shown any difference in 
endometrial cancer survival.  
A few others trials include agents such as cell cycle inhibitors, mitogen activated 
protein kinase (MAPK) -inhibition, gonadotropin releasing hormone (GnRH) -agonism, 
folic acid analogism, histone deacetylase inhibitors (HDAC) -inhibition, the monoclonal 
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antibody RAV12, CALAA-01 (RNA-interference), UCN-01 (protein kinase C 
inhibition) and cyclooxigenase (COX II)-inhibition. Again, as yet, these agents have 
failed to show any significant impact on endometrial cancer survival or played any role 
as a diagnostic or prognostic tool. 
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1.11 Novel markers used in this research 
project 
 
1.11.1 Tetraspanin CD151 
Tetraspanins are small membrane proteins expressed in a wide range of species from 
sponges to mammals, with each organism expressing a large number of tetraspanin 
family members. Numerous biological processes need tetraspanin input, such as 
fertilization, inflammation and infection, parasite as well as viral infection, synaptic 
contacts at neuromuscular junctions, platelet aggregation, maintenance of skin integrity, 
immune response induction, metastasis suppression as well as tumour progression.171 172 
CD151 is one of currently 33 proteins known in the mammalian tetraspanin 
superfamily.  
1.11.1.1 Architectural features of tetraspanins 
A defining feature of the protein family of tetraspanins is its transmembranous 
architectural structure that crosses the cell membrane four times (Figure 1.4, see page 
59). They have short amino- and carboxy-terminal tails, a small intracellular loop 
between transmembranous region 2 (TM2) and TM3, a small extracellular loop (ECL1) 
between TM1 and TM2 and a large extracellular loop (ECL2) between TM3 and TM4 
(Figure 1.5, see page 61). ECL2 can be subdivided into a mostly constant region and a 
variable region. The constant region may account for dimerization, the variable region 
for interactions with non-tetraspanin partner molecules.   
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Figure 1.4 
 
Transmembranous architectural structure-model of tetraspanin.       
(kind courtesy of F. Berditchevski, Birmingham, United Kingdom) 
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1.11.1.2 Locations of tetraspanins 
Apart from the general location in the cell membrane, tetraspanins are also abundant in 
membranes of various types of endocytic organelles, endosomes and exosomes, 30–100 
nm vesicles that are released by many cells. They derive from multivesicular bodies, 
which either fuse with lysosomes or fuse with the plasma membrane and release their 
intraluminal vesicles as exosomes. The molecular composition of exosomes reflects 
their origin from intraluminal vesicles and includes several tetraspanins. Exosomes are 
thought to constitute a potent mode of intercellular communication that is also 
important in tumour progression. Thus tetraspanins are able to communicate and travel 
within the cell with or without endosomes as well as leaving the cell in form of 
exosomes and multivesicular bodies (MVBs). Tetraspanin-enriched microdomains 
(TEMs) may appear similar to lipid rafts and indeed have common features. However, 
they are different structures: They are disrupted by Triton X-100 at 4°C and the 
signature molecules for classical rafts — glycosylphosphatidylinositol-anchored 
proteins and caveolin — do not associate with tetraspanins.  
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Figure 1.5 
 
Predicted 3-dimensional structure of tetraspanin.  
(kind courtesy of F. Berditchevski, Birmingham, United Kingdom) 
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1.11.1.3 Tetraspanin primary interactions 
Tetraspanins play a key role in the formation of complexes called the tetraspanin-
enriched microdomains (TEMs), which contain amongst other tetraspanins a number of 
other transmembrane receptors (e.g. integrins, receptors tyrosine kinases) and thus 
provide a signalling platform. Laminin-binding integrins particularly α3β1, α6β1 and 
α6β4 are most commonly associated with TEM formation and it has been shown that 
tetraspanins regulate integrin-dependent adhesion strengthening. Tetraspanins also 
associate with growth factor receptor, G-protein-coupled receptors and their 
intracellular associated heterotrimeric G-proteins, several peptidases, transmembrane 
proteins associated with tumour progression, immunoglobulin superfamily members 
and cytosolic signal transduction molecules. Palmitoylation of intracellular, 
juxtamembrane cysteines is thought to be required for initiating tetraspanin–tetraspanin 
web formation. This also seems to shield tetraspanins from lysosomal lysis and 
promotes increased cell–cell contact. The formation of the essential tetraspanin enriched 
microdomain is also partly dependent on the palmitoylation of specific integrins.  
 
1.11.1.4 Core activities of tetraspanins.  
Activities of tetraspanins vary considerably depending on the activation state of the cell 
as well as the surrounding tissue. Tetraspanins can act either directly, through their 
laterally associated partner molecules or, less frequently, through ligand binding. In 
addition, as a major component of exosomes, tetraspanins are likely to be involved in 
cross-talk between distant cells. According to Maecker et al. in the first review about 
tetraspanins: “Tetraspanins function via modulating, stabilizing or preventing the 
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activities of their associated molecules, which vary depending on the TEM 
composition”.172 Via biosynthesis, compartmentalisation, internalisation and recycling 
of integrins, or modulating of integrin signalling and trafficking tetraspanins play a key 
role in cell motility, adhesion, invasion and fusion.171 173 174  
 
1.11.1.5 Tetraspanin CD151 and tumour progression 
In vivo tumour cell migration through integrin-dependent pathways is key to the 
metastatic behaviour of malignant cells. Due to its strong binding properties with 
laminin binding integrins CD151 is well positioned to modulate integrin-dependent cell 
spreading, migration, signalling, and adhesion strengthening.175-177  
Integrin-tetraspanin complexes have been described to be critical for regulating cell 
invasiveness and controlling intercellular interactions, both of which play a critical role 
during the metastatic progression.178 Takeda et al. analysed CD151-null cells and tissue 
ex-vivo and showed selected alterations in cell outgrowth, migration, aggregation, 
proliferation, morphology and signalling.179 Consistent with the close association with 
laminin-binding intergrins they demonstrated that removal of CD151 by antisense, 
siRNA knockdown or knockout showed selective signalling defects with diminished 
phosphatidylinositol 3-kinase (PI3K), Akt, and Rac1 pathways and disruption of 
connections between laminin-binding integrins and at least 5 other proteins which 
resulted in impaired pathologic angiogenesis. They concluded that CD151 supports 
pathologic angiogenesis via the influence of laminin-binding integrins on endothelial 
cells. Furthermore CD151 depletion has been described to either increase 179 or decrease 
173 179
 cell motility. CD151 has also been shown to promote tumour cell intravasation 
and subsequent colonization of secondary organs. Blocking CD151 leads to a 
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significant increase in cell adhesion and a pronounced immobilization of the tumour 
cell, thus inhibiting migration and preventing cell dissociation and metastasis.180 
To investigate the role of CD151 in tumour metastasis further, CD151 cDNA was 
transfected into different tumour cell lines and it was found that these CD151 
overexpressing cells were more aggressive than the control cells with enhanced motility 
and invasion.181 182 Testa et al. reported that CD151 is involved in an early step in the 
formation of metastatic foci, such as arrest, extravasation, and/or migration into the 
connective tissue stroma of the secondary organ.173 
However, the role of CD151 in proliferation and metastasis of non-hematopoietic cells 
remains controversial. There were no obvious proliferative defects in CD151-deficient 
mice and humans.180 183 Also, deletion of CD151 did not affect proliferation of primary 
endothelial cells on Matrigel in vitro.179 Yet Geary et al showed that primary 
keratinocytes on a laminin substrate were impaired when the cells were CD151 
negative.184 It is possible that CD151 may play a greater role in immunocompromised 
tumour cells rather than in normal cells.185 In malignancy CD151 appears to be involved 
in both - pro-invasive- (rapid migration) and anti-invasive functions (stable cell 
junctions).178 Overexpression as well as underexpression of CD151 has been observed 
in different tumour types. Novitskaya et al. suggested that variations in CD151 effects 
might be cell-type specific and/or also dependent on the individual host 
microenvironment. 186 CD151 has been investigated in vivo in a number of cancer 
types.  
Prostate cancer: Ang et al. investigated prostate cancer collecting tissue specimens from 
76 primary prostate cancers and 30 benign prostate hyperplasia (BPH) controls.187 
CD151 expression was found to be significantly higher in prostate cancer specimens 
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compared with BPH specimens (p < 0.001). The strongest staining was observed in 
poorly differentiated tumour specimen, whereas well differentiated cancers expressed 
the weakest staining for CD151 (p < 0.001). CD151 expression showed a negative 
correlation to overall survival, i.e. higher levels of CD151 were associated with poorer 
prognosis. This effect was independent of the patients’ age or preoperative prostate-
specific antigen values and superior in the predictive ability of the Gleason score. They 
concluded that CD151 had better predicting value for the clinical outcome of prostate 
cancer patients than does the traditional histologic grading method (Gleason grading). 
Lung cancer: Non small cell lung cancer was investigated by Tokuhara et al. using 
reverse transcription-PCR and immunohistochemistry.188 Whereas 86 out of the 146 
collected tumour specimens were positive for the CD151 gene, 59 had tumours that 
were negative for the CD151 gene. The overall survival rate of patients with CD151-
positive tumours was lower than that of CD151-negative patients (51.9% versus 73.1%; 
p = 0.013). They concluded that high CD151 gene expression in lung cancer may be 
associated with a poor prognosis. 
Breast cancer: Yang et al. postulated an acceleration of growth caused by CD151 
regulating α6 integrin activity.189 They observed an increased CD151 expression in a 
subset of human breast cancer samples, particularly those of high grade and/or triple 
negative tumours – oestrogen receptor (ER) negative, progesterone receptor (PR) 
negative and human epidermal growth factor receptor 2 (Her 2) negative – which 
appeared to be a significant marker for poor outcome. In this study CD151 ablation 
markedly reduced migration, invasion, spreading, and signalling of basal-like mammary 
tumour cells and showed signs of disrupted epidermal growth factor receptor (EGFR)-
α6- integrin collaboration. In a basal-like mammary tumour cell line, they demonstrated 
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that CD151 ablation delayed tumour progression. They concluded that CD151 is a 
potential therapeutic target with relative selectivity (compared with laminin-binding 
integrins) for pathologic rather than normal physiology. 
Colorectal cancer: Interestingly Chien et al. demonstrated very different results.190 They 
investigated a cohort of 137 paired cases of colorectal carcinoma and normal colon 
tissues examined by immunohistochemical staining and western blot for the expression 
of CD151. They showed that expression of CD151 protein was reduced in the colon 
cancer tissues compared with the surrounding normal tissues. One explanation was the 
observation that the expression of CD151 was negatively regulated by hypoxia 
inducible factor-1- dependent hypoxic stress. Suppression of CD151 by hypoxia caused 
the detachment of cancer cells from the surrounding matrix and neighbouring cells 
whereas restoration of CD151 expression during re-oxygenation facilitated the adhesion 
capacity.  
Urothelial Carcinoma: Recently Minner et al. published data from a tissue micraoarray 
with 664 tumour specimen. Like Chien et al. they observed an association between 
decreased levels of CD151 and advanced tumour stage and high grade in urothelial 
bladder cancer.191 
 
Given the above findings of CD151’s potential central role in cell motility and 
metastasis, its’ clinical behaviour in hormonally dependent tissues such as breast cancer, 
as well as its’ so far controversial effects observed, CD151 was found to be a highly 
interesting and suitable marker for investigation of poor prognosis endometrial tumours 
in which tetraspanin activity has never been investigated. 
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1.11.2 Clusterin 
Clusterin is a glycoprotein that has a nearly ubiquitous tissue and fluid distribution, 
found amongst others in breast, prostate and kidney.192 It was previously also known as 
„apolipoprotein J”, “testosterone-repressed prostate message-2”, and “sulfated 
glycolprotein-2”. Located on chromosome 8p21-p12 Clusterin (CLU) is coded by a 
single nine-exon gene spanning 17kb. The gene encodes 3 CLU isoforms, and 
differences in subcellular localisation give direction to the understanding of their 
function.193 
CLU has been implicated in various cell functions including apoptotic cell death, cell 
cycle regulation, cell adhesion, tissue remodelling, and immune system regulation 
involved in physiologic or pathologic processes such as carcinogenesis and tumour 
progression.194-196 Such an expression pattern is pointing at a potential key role in 
cellular homeostasis, and the protein is known to have both pro-apoptotic and 
anti-apoptotic functions.  
 
1.11.2.1 Clusterin isoforms 
This functional dichotomy may be related to at least three isoforms, two of which are 
translated into a secreted, cytoplasmic 80kDa (glycosylated, proteolytically cleaved) 
and 60 kDa (non-glycosylated) clusterin protein (sCLU), and one of which is alternately 
spliced and translated into a nuclear clusterin protein (nCLU, ~ 55 kDa). Reacting to 
various types of cell damage, nCLU is released inducing apoptosis 197, whilst sCLU 
(75–80 kDa) seems to act as an anti-apoptotic/pro-survival or a proliferative protein in 
certain cancer cells.198 199  
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1.11.2.2 Clusterin and malignancy 
A multitude of data has been generated about the roles of clusterin in malignant disease 
with seemingly conflicting information indicating in some cancers an oncogenic or 
cancercell-cytoprotective activity 200 and involvement in tumourigenesis while in other 
cancers data are suggestive of a tumour suppressor role. Furthermore, studies have 
observed decreased as well as increased levels of expression within the same tumour 
entity.197 201 202 
 
1.11.2.3 Clusterin as an oncogene 
A number of studies have shown significant overexpression of CLU in disease and 
normal tissue, in animal models and cell lines indicating an oncogenic role. Furthermore 
increased expression correlates with disease severity in a number of cases. In colon 203 
204
 ovarian 205 206, breast 207 208, endometrial 209 and bladder cancer 210 clusterin 
overexpression was associated with disease progression, recurrence and survival. In 
renal cancer multivariate analyses revealed that strong expression of clusterin was an 
independent predictor of tumour recurrence and overall survival.211 In hepatocellular 
carcinoma univariate analysis showed recurrence free survival was significantly lower 
in patients with strong clusterin expression.212 In cervical cancer Watari et al 
demonstrated in his cohort of patients who all underwent systematic lymphadenectomy 
and radical surgery that CLU positivity was an independant prognostic marker for 
advanced disease.213 
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1.11.2.4 Clusterin as a tumour suppressor 
 
There is also a variety of publications describing underexpression or downregulation of 
CLU in tumourigenesis indicating a potential role as a tumour suppressor gene. 
In prostate cancer such a possible role has been suggested by Caporali et al.214 They 
found that in transgenic adenocarcinoma mouse prostate (TRAMP) mice which 
spontaneously develop prostate cancer, CLU was downregulated during prostate cancer 
onset and progression. Such a role is supported by Rauhala et al. who found clusterin 
expression to be significantly reduced in untreated and hormone-refractory prostate 
carcinomas.201   
In colon cancer cell lines Chen et al found that transient transfection of clusterin directly 
enhanced basal and chemotherapy-induced apoptosis. Furthermore clusterin-induced 
apoptosis was inhibited by antisense clusterin.215 In fine needle aspirates of pancreatic 
adenocarcinoma Jhala et al. found clusterin staining significantly less frequently than in 
normal reactive ductal epithelium.216 
However, some studies have found that expression may not necessarily be related to 
disease progression or tumour size.217 216 218 
 
1.11.2.5 Clusterin isoforms in malignancies 
Contradictions and alternative hypotheses still exist about the various roles of clusterin, 
and researchers are still unsure whether CLU is now a positive or a negative modulator 
of mammalian tumourigenesis.219 The likely answer is that it is able to function in both 
ways.  
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This might be possible and explained through the different isoforms as well as 
understanding and discerning the changing biological requirements of a tumour in its 
course over time, from its early development through to survival under the pressures of 
environment, hormones, chemotherapy etc. As an example Pucci et al found clusterin in 
a nuclear localization in healthy colonic mucosa being consistent with the involvement 
of the proapoptotic nuclear clusterin form in the regulation of cell cycle progression and 
in cell death induction.220 Progression towards tumour and particularly towards high-
grade and metastatic carcinoma saw clusterin being distributed to the cytoplasm. Protein 
extracts from such cells documented the complete loss of the pro-apoptotic nuclear form 
and a cytoplasmic overexpression of the highly glycosylated anti-apoptotic form. These 
data suggest that the controversial data on clusterin function in tumours may be in part 
related to the pattern shift of its isoform production.220 
 
1.11.2.6 Clusterin in targeted therapy 
Antisense oligonucleotide (ASO) therapy against clusterin is currently used in clinical 
trials to evaluate its efficacy in improving androgen deprivation therapy and/or prevent 
chemoresistance.221 222 Clusterin has also been suggested to be a potential stool 
biomarker for colon cancer screening.223 In breast cancer, results from a phase II trial 
where clusterin ASO therapy was added to a taxane chemotherapy, showed no increase 
in treatment response.224 
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1.11.2.7 Clusterin and endometrial carcinoma 
In endometrial carcinoma Ahn H.J. et al. found that that sCLU was overexpressed in 
endometrioid endometrial carcinoma (EEC) but not in papillary serous type cancers 
compared to normal endometrium. 209 The biological role of over-expression of sCLU 
in the endometrioid carcinoma might be anti-apoptotic or pro-survival, similar to the 
situation in other carcinomas. 
 
 
In view of the central role of CLU in tumourigenesis and the urgent need for molecular 
factors to distinguish the two phenotypes of endometrial carcinomas, Clusterin was 
chosen as one of the molecular markers to investigate in the present study. 
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1.12 Hypothesis 
 
This study was set out to answer the following hypotheses: 
1. Based on clinical observations we hypothesise that G3 endometrioid endometrial 
carcinoma belongs to a group of poor outcome uterine malignancies which 
fulfills more criteria of type II rather that type I endometrial carcinoma.  
2.  Based on the findings in breast-, prostate- and colon carcinoma we hypothesise 
that CD151 is a useful prognostic marker for poor prognosis endometrial 
carcinoma. 
3.  Based on the findings in breast-, prostate-, ovarian- and colon carcinoma we 
hypothesise that Clusterin is a useful prognostic marker for poor prognosis 
endometrial carcinoma. 
4.  Investigating the different groups within poor prognosis endometrial cancers we 
hypothesise that CD151 and/or Clusterin will provide new information to 
characterise these groups. 
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1.13 Aims of the thesis 
 
1.  To compare immunohistochemistry profiles and survival outcome of grade 3 
endometrioid cancers with type 2 cancers of the cohort investigated. 
2.  To assess the prognostic significance of CD151 
3.  To assess the prognostic significance of Clusterin 
4.  To compare the expression profiles of CD151 and Clusterin with the clinical and 
pathological features of the cohort investigated. 
5.  To compare the expression profiles of CD151 and Clusterin with the expression 
profiles of oestrogen receptor (ER), progesterone receptor (PR), p53 and Her-2 
of the cohort investigated.   
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CHAPTER 
2 MATERIAL AND METHODS 
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2.1 Setting 
 
Gloucestershire Hospitals NHS Foundation Trust (GHNHSFT), Gloucestershire, United 
Kingdom. All patients in this study were seen and treated in Cheltenham General 
Hospital and/or Gloucestershire Royal Hospital, Gloucester. 
 
2.2 Patients and Specimen characteristics 
 
Upon approval from the Southmead research ethics committee (REC ref.07/H0102/64), 
archived formalin-fixed and paraffin-embedded tissue blocks and corresponding 
pathology reports were collected from all patients who underwent treatment for 
International Federation of Gynaecology and Obstetrics (FIGO) stage IA–IV uterine 
cancers at the Gloucestershire NHS Foundation Trust Hospitals between 01.01.1997 
and 31.12.2002. Histology types grade 3 endometrioid endometrial adenocarcinoma 
(G3 EEC), uterine papillary serous carcinoma (UPSC), clear cell carcinoma (CC), 
carcinosarcoma (MMMT), sarcoma and malignant uterine epithelial tumours of mixed 
histology were selected. Architectural grading was based on the degree of glandular 
differentiation in accordance with the FIGO guidelines.  
Clinicopathological information and survival data were abstracted from an ongoing 
regional prospectively collected clinical database held at the South West Public Health 
Observatory (SWPHO), Bristol, United Kingdom.  
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Figure 2.1 
South West Public Health Observatory (SWPHO) data sheet for endometrial 
cancer by the South West Cancer Intelligence Unit. 
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The information in this database is gathered by standardized data forms which have to 
be completed at the point a certain diagnose has been made and a treatment regimen 
commenced (Figure 2.1, see page 76).   
This form is designed for all patients with endometrial cancer and routinely completed 
by a member of the gynaecology-oncology team of the GHNHSFT. The purpose and 
benefit of the SWPHO data sheet is to provide detailed information on how each 
individual patient has been surgically and systemically treated. It is divided into three 
sections: surgery, histopathology and oncology.  
The surgical section comprises details on the date of operation, the fact whether surgery 
has been conducted as part of a clinical trial and whether it is a case of primary disease 
or tumour progress or recurrence. The name of the surgeon and his/her level of training 
is disclosed and details given on the surgical approach such as the way of incision or via 
laparoscopy, clinical findings regarding the extent of disease and organs involved as 
well as details of tissue and/or organs removed. The histopathology section renders 
information such as the histology reference number and date of reporting, comprises 
histological typing, grading, detailed description of involved organs such as depth of 
endometrium invaded, parametrial, ovarian, cervical and vaginal involvement, number 
and region of lymphnodes sampled and their tumour involvement, metastasation to 
distant organs, the cytology of peritoneal washings and the final TNM and FIGO stage. 
The oncology section comprises details on adjuvant therapy such as radio- or 
chemotherapy. The oncology number is disclosed and information given whether 
treatment has been subject to a clinical trial. The intention of treatment is stated – 
whether radical, curative or palliative. In the case of radiotherapy treatment the regimes 
of external beam and/or brachytherapy are outlined in view of site and size, number of 
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fractions, the total amount of radiation used measured in gray (Gy) and the overall 
treatment time. In the case of chemotherapy it is stated whether the intention and timing 
of treatment was concomitant, adjuvant or palliative, the number of cycles of the 
specific regime used and information is given on the extent of the response under 
treatment – complete or partial regression (CR/PR), stable or progressive disease 
(SD/PD). 
All patients were kept under regular surveillance for 5 years, follow-up details for 
longer than five years were abstracted from hospital records from other attendances.  
The survival data used in this study are believed to be very robust due to the centralized 
computed documentation system covering a whole county. As long as a patient was 
resident in the county, all hospital attendances throughout the entire region would be 
documented in the GHNHSFT computer system. Additionally, every single blood 
sample obtained in one of the NHS facilities or in any GP surgery in the region would 
be visible via this system and thus proof at least that the patient in question was alive at 
the given date and where she was last seen. Additionally, counter-checking all patients 
in the in-house database of the GHNHSFT Oncology Services provided extra safety 
particularly by identifying recurrence/tumour progression data. Clinical endpoints were 
survival or death of disease or other causes or date of recurrence as recorded in the 
hospital notes. Data on death and cause of death was cross referenced against cancer 
registry data to ensure accuracy. 
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2.3 The tissue microarray 
 
Tissue microarrays (TMAs) consist of paraffin blocks where up to several thousand 
individual tissue cores have been inserted in an arrayed fashion. They are produced by a 
method of serially re-locating tissue from many conventional histology paraffin blocks 
into a single new block and then cut into fine sections such that tissue samples from 
multiple patients or donor specimen are arrayed on a single microscopic slide to be 
assayed and visualised simultaneously.  
This is done by using a hollow needle attached to a microarrayer to biopsy standard 
histology sections and placing the core into a precise position in an array on a recipient 
paraffin block. The microarrayer provides repetitive and precise positioning of the 
tissue-cores up to a variance of less than 0.1 mm. This technique, originally described 
by Wan et al in 1987 in the Journal of Immunological Methods was a modification of 
Battifora's "sausage" block technique where tissue cores were placed in specific pre-
formed slots in a block.225 226 The technique gained international attention when 
Kononen and colleagues in the laboratory of Ollie Kallioniemi published it in Nature 
Medicine in 1998. 227  
These miniaturized collections of tissue spots result in a significant increase in 
throughput for in situ examination of gene status or protein expression from archival 
specimens. The simplification of specimen handling and processing enables researchers 
to extend their cohorts exponentially which improves the quality and significance of the 
findings about the biomarker investigated. Processing quality is further improved by the 
fact that all specimens are arrayed on a single slide which means staining conditions are 
identical and consistent with precisely the same antibody dilution. Additionally, the 
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possibility of looking at a series of biomarkers simultaneously in exactly the same 
specimen, time and circumstances again improves quality and reliability. 
All available methods for examination of histological sections, including 
immunohistochemistry, in situ hybridization, DNA ploidy analysis, nuclear 
morphometry, and fluorescent in situ hybridization can be performed on sections from 
TMA blocks. Many clinical specimens contain limited tissue for study. TMAs can 
expand the number of studies that can be performed from either limited or extremely 
valuable specimens. TMAs have been validated as useful tools for the evaluation of 
various biomarkers, especially in oncology patients.  
 
2.4 Tissue microarray construction 
 
Tissue microarray construction requires detailed planning of successive basic steps 
which are outlined in accordance with recommendations recently summarised by 
Professor Manuel Salto-Tellez, Chair of Molecular Pathology at Queens University 
Belfast presented at the Biomarkers, Biostatistics and Novel Clinical Trial Design 
workshop held in September 2012 in Nottingham. 
(http://ncrndev.org.uk/downloads/BI%20CSG%20Workshops/TMA/Salto-Tellez.pdf). 
Listed below are the 10 recommended basic steps of tissue microarray construction 
whilst each step is described in detail if required within the following chapters. 
1. Collection of the pathology files of the cases included in the study cohort.  
2. Retrieval of the histology slides, review of histology and marking out  
representative areas on a H/E stained slide by a pathologist. 
3. Retrieval of paraffin blocks. 
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4. Marking out areas to be punched on paraffin blocks using H/E slide as guide. 
5. Selection of punch size and recipient block. 
6. Preparation of tissue microarray map. 
7. Punching out tissue cores and transfer to recipient block. 
8. Cut H/E slide from arrayed block 
9. Review of histology 
10. Repair of array block by replacing non-representative tissue cores 
 
2.4.1 Selection of tumour blocks 
A pathologist with a special interest in gynaecologic pathology reviewed all 
hematoxylin- and eosin-stained (H&E) slides of each tumour to confirm the original 
diagnosis of endometrioid, uterine serous papillary or clear cell endometrial cancer, 
sarcoma, carcinosarcoma or mixed histology. Corresponding paraffin blocks were then 
obtained from the tissue archives. A representative paraffin-embedded tumour block 
was selected after review of H&E- sections and two separate areas of tumour were 
marked on the slide and corresponding tissue block. As the block might contain more 
than one tissue diagnosis of interest for obtaining tissue cores for a TMA, each circled 
tissue diagnosis on the slide was also assigned a number. (Figure 2.2, see page 82) 
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Figure 2.2 
 
Paraffin embedded tumour tissue blocks. 
 
2.4.2 Design and mapping 
The design and planning of the tissue microarray construction was carefully conducted 
to facilitate the following requirements: 
1. Logical and successive collection of tissue specimens to avoid missing or 
duplication of cases. 
2. Design of a basic system which would be repeatable for each array-block yet 
render every block, and thus slide, individually recognisable at a glance. 
3. Precise documentation and mapping system of every single position of tissue 
specimens to render the localisation of each individual case in any given sector 
of the block swiftly and failsafe and to 
4. Aid visual detection of differing slides and specimens in the same assignment. 
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The basic metric dimensions required for a tissue microarray paraffin block are such 
that its sections fit on a standard microscope glass slide of 25x75mm. The use of 
standard microscope glass slides of 25x75mm as carriers of the sectioned tissue 
microarray specimen is advisable to ensure routine processing, quick and safe 
throughput, multiple use by various people and institutions as well as storage and 
postage. To be safely placed on the standard microscope glass slide the mounting 
paraffin block for the tissue microarray is approximately 20 x 45 mm in dimension. 
 
The standard size of a single tissue core in a tissue microarray core is 0.4 to 1 mm in 
diameter. Cores can be placed as close to each other in the paraffin block as the physical 
practicality and precision of an arrayer machine allows. However, in order to retain the 
stability of the paraffin structure surrounding the tissue cores as well as visibility and 
ability to keep them separate during the processing of the blocks and slides, it is 
advisable to space the cores 0.5 to 2 mm apart.  
For this study it was calculated to fit 6 to 8 rows of tissue specimen into one paraffin 
block, each row consisting of 10 to 15 tissue cores, each core 0.6mm in diameter and 1 
mm apart from any given neighbour. Thus a single paraffin block would contain up to 
120 tissue cores. Given 156 tumour cases with at least two samples each plus a certain 
number of control samples it was estimated to require space for 400-500 tissue cores. 
Therefore, it was decided to produce 5 tissue microarrays in 20 x 45 mm paraffin 
blocks. 
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2.4.2.1 Tissue microarray block and slide 
identification system 
Having more than 1 tissue microarray with each of them containing specimens all of 
which should undergo exactly the same number and type of experiments, an 
identification system is required with the ability to differentiate the microarrays from 
each other and recognise them individually and immediately at a glance. In the case of 
this study it was necessary to devise a system to identify and differentiate 5 tissue 
microarray blocks and respective slides and also be able to retain their order at all times. 
Figure 2.3 (see page 85) depicts an exemplary microarray constructed for this study 
demonstrating the arrangement and pattern of tissue cores. 
 
1. There are 12 core positions (i.e. positions to receive tissue cores) to each row 
with a maximum of 7 rows per slide. 
2. The top and bottom row (row 1 and 7) are the “block-identification-rows” with 
at least one core at either end (position 1 and 12). 
3. Positions 1 to 5 in the top and bottom row are filled with placental tissue control 
cores according to the number of the tissue microarray block. Thus, “TMA 
Block 1” has a tissue core at position 1 and 12, “TMA Block 2” has tissue cores 
at position 1 and 2 and 12, “TMA Block 2” has tissue cores at position 1-3 and 
12 etc. The number of cores in the top and bottom row on the left side is well 
visible with the naked eye and renders them instantaneously identifiable within 
the 5 blocks of TMAs of this study. 
4. In the very bottom left corner, below position 1 of row 6, a single tissue core is 
placed to avoid any chance of disorientation on the future TMA slide due to 
 85 
 
handling errors of a slide. This core ensures the correct position/orientation the 
glass slide is held once a TMA is sliced up and placed on a glass mount. If the 
slide is inadvertently turned up-side down or sideways, this single core would be 
found (falsely) either above row 1 or below position 12 of row 6, thus the slide 
be recognised as wrongly orientated or held. 
 
 
Figure 2.3 
 
TMA block 5 – Exemplary paraffin block with tissue cores embedded. 
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2.4.2.2 Tissue core identification and mapping 
system 
An essential requirement for the TMA is a robust link between each core to its original 
donor tissue and to the patient’s anonymized clinical dataset. A code was developed 
indentifying each tissue core in the TMA encoding the following information: 
1. The first number refers to the position of the tumour in the database 
2. The double letters refer to the initials of the patient’s name. 
3. The 6 digit number refers to the year of collection and the histology number of 
the tumour. 
4. The last letter refers to the duplicate number of this tissue specimen, i.e. A or B. 
Example: 12-LE-97 3898 A. Given the slide identification system, explained above, 
only row 2 to 5 in the TMA blocks contained tumour specimen of the study cohort. All 
other positions were filled with control tissue. Figure 2.4 (see page 87) depicts the 
specimen reference spreadsheet identifying every position of each tissue core in the five 
TMA blocks. Each Excel spreadsheet maps out the pattern and position of every tissue 
core at a glance. 
 87 
 
Figure 2.4 
control           control  
2-HV-97 5659 2-HV-97 5659 3-EV-97 5361 3-EV-97 5361 5-TJ-97 1079 5-TJ-97 1079 7-HK-97 4329 7-HK-97 4329 8-BM-97 8597 8-BM-97 8597 9-RS-97 8239 9-RS-97 8239  
A B A B A B A B A B A B  
10-NM-97 8988 10-NM-97 8988 11-WJ-97 14774 11-WJ-97 14774 12-LE-97 3898 12-LE-97 3898 13-GA-97 4764 13-GA-97 4764 14-MD-97 14145 14-MD-97 14145 15-ES-97 16017 15-ES-97 16017  
A B A B A B A B A B A B  
16-HG-98 7569/70 16-HG-98 7569/70 17-OK-98 6256/7 17-OK-98 6256/7 18-KJ-98 7572 18-KJ-98 7572 19-CM-98 1412 19-CM-98 1412 20-PM-h19809849 20-PM-h19809849 21-HB-h19808752 21-HB-h19808752  
A B A B A B A B A B A B  
23-WC-98 7726 23-WC-98 7726 24-JD-h9814398 24-JD-h9814398 25-ME-h19813062 25-ME-h19813062 26-PM-h19815277 26-PM-h19815277 27-WB-99 3039 27-WB-99 3039 28-BJ-h19906145 28-BJ-h19906145  
A B A B A B A B A B A B  
29-CM-99 03781 29-CM-99 03781 30-DD-99 6896 30-DD-99 6896 31-BB-h19909114 31-BB-h19909114 32-LK-h19904777 32-LK-h19904777 33-BV-99 05434 33-BV-99 05434 34-LL-h19979498 34-LL-h19979498  
A B A B A B A B A B A B  
control           control  
control             
 0,6 mm CORE, 2mm GAP  BLOCK 1 EmCA 2-34         
             
 
Tissue core identification and mapping system. The Excel spreadsheet maps out the view on top of TMA block 1. Each study tissue 
core has an individual code consisting of a number followed by two letters and again followed by a number each separated by a 
hyphen. The first number refers to the position of the tumour in the database. The double letters refer to the initials of the patient’s 
name. The 6 digit number refers to the year of collection and the histology number of the tumour. Sometimes the last number is 
headed by the letter h which is identifying the histology number of the tissue instead. A capital letter in the box below the code 
refers to the duplicate number of this tissue specimen, i.e. A or B. 
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2.4.3 Instrumentation and equipment set-up 
A simple, manually operated tissue microarrayer by Beecher Instruments (Model: 
Manual Tissue Microarrayer MTA-1) was used. (Figure 2.5, see below). The central 
part is a rotating turret with two punch needles mounted on it:  
Needle 1:  To punch a regular array of holes in a recipient block. 
Needle 2:  To extract cores from marked regions of donor tissue blocks and  
inject these cores into the holes of the recipient block.  
Needle 2 is slightly thinner than needle 1 so that the content of needle 2 fits firmly into 
the pre-formed hole. X-Y micrometers define the coordinates of the array and its 
micrometer adjustment knobs (Figure 2.6, see page 89) facilitate adjustment of cored 
tissues in straight rows, easily visualised in the array setup.  
 
Figure 2.5  
 
Mounted punch needles on tissue microarrayer by Beecher Instruments. 
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Before the arraying process begins each donor tissue block and corresponding slide pair 
are arranged in the order that they will be used following the map design. Prior to 
placement in the arrayer the recipient blocks are “faced off” on both front and back 
sides using a rotary microtome to ensure that the block face is smooth and all arrays 
made will be in the identical plane. This minimizes the amount of block realignment 
that will be necessary during sectioning and helps to optimize the number of complete 
sections that an array block will yield. The recipient block is then placed into the base of 
the arrayer. 
 
Figure 2.6 
 
Manual Tissue Microarrayer MTA-1 by Beecher Instruments with visible 
adjustment manuals for precise movement across the paraffin block.  
Micrometer 
adjustment knob, 
x-axis 
Micrometer 
adjustment knob,  
y-axis 
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To ensure the alignment of the punch needles, the recipient needle (needle 2) is moved 
into position and makes a mark in the paraffin. This is then repeated for the donor 
needle (needle 1) so that both marks are precisely at the same position. The needles are 
moved to the position of the first punch with the x- and y-axis micrometer adjustment 
knobs. The position of the punches over the block is assessed by gently pushing down 
on them until a mark is made in the paraffin, making adjustments with the micrometer 
knobs until the desired position is attained. Then the micrometer is zeroed for the X and 
Y axis. At last the “depth stop” is adjusted, which determines how deep the punch will 
be forced into the recipient block. Only the depth of the recipient core can be set by the 
depth stop. There is no depth stop to determine or control the depth of the donor core 
due to the varying thickness of the donor tissue block, which will naturally determine 
the limit of the depth or length of the cores that can be taken. It is important to choose 
tumour tissue blocks of appropriate depth for the depth of the thinnest block will 
determine the maximum thickness of the TMA and dictate the maximum available 
sections cut from this TMA block. The arrayer is then aligned and ready to be used for 
one specific block. 
 
2.4.4 Tissue microarray construction 
When the donor blocks, recipient block and arrayer are set up the actual microarray 
construction can begin. Since TMA construction with the equipment described above is 
a heavily formalized and structured process the 10 following steps are an amended 
version of the to detailed instruction published by Helen Fedor et al. in 2005.228 
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1. Pressure is applied to the top of the turret to bring down needle 1 into the 
recipient block. A squeezing motion is used to push the tissue core into the 
paraffin.  
2. The arm of the punch is rotated to the left and then back to the right to free the 
core from the recipient paraffin block. 
3. The pressure on the turret is released and the spring brings the turret back to its 
resting position. Here the stylus is pressed down through needle 1 to eject the 
paraffin core from the punch which is then discarded. The length of the paraffin 
core should correspond with the predetermined depth stop. 
4. The turret is swung to the right to allow the donor needle (needle 2) to be 
brought into proper position. Then the bridge is placed over the recipient block. 
5. The donor block with the area of interest circled is placed on the bridge under 
the needle and a punch is taken from the inscribed sample area by repeating the 
procedure for removing the paraffin core from the recipient block. 
6. The bridge and donor block are removed.  
7. The core is inserted into the recipient block by bringing the turret down until the 
lower punch surface is directly over the hole that was just created. With 
continuous pressure on the turret the stylus is slowly push guiding the tissue core 
into the hole while expelling the tissue from the punch needle (needle 2). 
8. The x-axis micrometer knob is moved precisely 1.0 mm and the procedure is 
repeated across the row until the last core has been placed. 
9. The x-axis micrometer knob is then moved to go back to position zero and  
the y-axis micrometer knob is moved 1.0 mm down and the procedure repeated 
until the block is complete. 228 
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Two tissue cores of 0.6mm diameter and approximately 5 mm in length were taken 
from each donor paraffin block corresponding to the marked area. The cores were set at 
1mm intervals, named A and B, to decrease the risk of aberrant results due to tumour 
heterogeneity. The tissue array was monitored after completion by a hematoxylin stain 
and in case of lack of visible tumour cells a duplicate biopsy was processed. The quality 
of the tissues in the arrays was in general excellent with preserved morphology. (Figure 
2.7, see page 93). 
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Figure 2.7   
 
The 5 completed TMA blocks of this study. 
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2.4.5 Tissue microarray block sectioning 
On completion of the array block sectioning was conducted according to the following, 
protocol: 
1. The blocks were sealed in an oven for 15 min at 37˚C face down on a clean glass 
slide. This facilitated the adherence of the cores to the walls of the punches in 
the recipient block. 
2. Maintaining the slide/block combination the complex was then removed from 
the oven and gentle and even pressure applied to even out irregularities in the 
block surface and possible bulging of the block centre which might occur during 
array construction. 
3. The slide/block combination was then placed onto a block of ice until it was 
completely cooled down before disassembly. 
4. With a microtome 4–5 µm sections were cut off the block, picked up with a fine 
celluloid tape and placed on 30˚C warmed slides ensuring that all sections were 
placed in the same orientation. 
5. Slides were dried overnight in vertical position. 
6. After drying the slides were placed front to back and put into a stack, wrapped 
with parafilm label, and stored at -20°C. 
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2.5 Immunohistochemistry 
 
2.5.1 Antibodies used 
In this study the following antibodies were used for immunohistochmistry (See Table 
2.1 below). 
 
Table 2.1 
GENE/ 
ANTIBODY 
SPECIES SOURCE EPITOPE DILUTION 
CLU Mouse monoclonal Vector 7D1 1:200 
CD151 Mouse monoclonal Leica 
Microsystem 
NCL-
CD151 
1:50 
ER Mouse monoclonal Dako 1D5 clone 1:35 
PR Mouse monoclonal Dako 636 clone 1:35 
P53 Mouse monoclonal Dako D-07  1:50 
Her-2 Mouse monoclonal DCS-System  SP3clone 1:400 
 
Antibodies used in this study. CLU = clusterin, ER = oestrogen receptor, PR = 
progesteron receptor. 
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2.5.2 Immunohistochemical staining of Clusterin and CD151 
with low temperature antigen retrieval 
 
2.5.2.1 Solutions 
Antigen retrieval buffer    Tris buffered saline (TBS) pH 7.6 
1mMol EDTA      6.05g Tris 
0.1% Tween20      8.76g NaCl 
Water        1L Water 
(pH adjusted to pH 7.6 with 1Mol HCl.) 
 
2.5.2.2 Procedure 
All slides were incubated for 10 minutes in 0.3% hydrogen peroxide in methanol to 
block endogenous peroxidase activity and then washed in running tap water. Sections 
were incubated in antigen retrieval buffer on a hotplate stirrer at 600rpm, 65°C for 
16hrs. Immunostaining was carried out in the Shandon Sequenza Immunostaining 
Station (Thermo Electron Corp. US) to ensure consistent staining. All slides were then 
mounted on to standard coverplates (Thermo Electron) and washed in TBS (Tris-
buffered saline) for 5 minutes. Next, 100µl of primary antibody was applied at the 
appropriate dilution in TBS and incubated at room temperature for 1hr. In the absence 
of known and tested dilutional antibody levels for endometrial tissue or endometrial 
cancer, dilutional levels previously employed for breast cancer were used. The antibody 
solution was then removed and the slide washed in 0.1% Tween-20 TBS for 5 minutes. 
2 drops of Dakochemate Envision Secondary (Dako) were then placed on each section 
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and again incubated for 30 minutes. The slides were then washed with 0.1% Tween-20 
TBS for 5 minutes. The coverplates were removed from the slides and the slides placed 
on to a staining rack. The slides were then rinsed again with TBS. The staining was 
visualised by incubating with chromagen (DAB, Dako) for 5 minutes or Novared 
(Dako) for 30 secondss. Following visualisation, the slides were placed in coplin jars 
and washed in water. The slides were then counterstained in haematoxylin (Sigma-
Aldrich Ltd, Gillingham, Dorset, UK-Aldrich) for 30 seconds and rinsed in hot water 
for 2 minutes, followed by cold water for 5 minutes. The slides were then dehydrated by 
sequential incubation for 5 minutes in IMS (industrial methylated spirit) and xylene. 
Following dehydration, after the xylene had evaporated from the slides, coverslips were 
applied with DPX mountant (BDH chemicals, Merck, US). 
 
2.5.3 Immunohistochemical staining of ER, PR and p53 
2.5.3.1 Solutions 
Antigen retrieval buffer   TBS Buffer pH 7.4  
2.10g Citric Acid     1Lof TBS concentrate (Dako, M1061D) 
1L distilled water    9L distilled water 
(Buffered to pH 6 with 10% NaOH) 
 
2.5.3.2 Procedure 
The formalin fixed, paraffin embedded 4µm sections of tissue were cut serially onto 
APES slides with known positive (in house) controls for validation.  For the staining of 
oestrogen receptors (ER) the 1D5 clone (Dako, Code M7047) was used at a dilution of 
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1:35, for progesterone receptors (PR) the PgR 636 clone (Dako; Code M3569) was used 
at a dilution of 1:35 and for p53 the D-07 clone (Dako, Code M7001) was used at a total 
protein concentration 11.9g/l, used at dilution 1: 50. 
Antibodies were titrated and diluted using Dako REAL diluent (Dako, S2022). Negative 
controls were employed using a 1:200 dilution of antibody diluent in TBS Tween pH7.4 
buffer instead of a primary antibody and subsequently stained in the following method. 
Slides were taken down to water through 2 changes of xylene (2 x 5minutes) and 2 
changes of IMS (2 x 5 minutes) then rinsed in running tap water for 10 minutes.  
Heat induced epitope retrieval (HEIR) was carried out using Antigen Access Unit (A. 
Menarini Diagnostics, MP-2002-CE) using an in-house citrate buffer pH6 (Department 
of Pathology, Cheltenham General Hospital, GHNHSFT). HEIR had been standardised 
to 125°C and 15-20bar for 30 seconds with cooling phased down to 90°C for 3 minutes 
(complete cycle = 50 minutes), slides were left at room temperature for 10minutes and 
cold distilled water slowly added. Slides were then transferred into TBS tween buffer 
pH7.4 (Dako, M1061D, 10x Concentrate) before loading onto the staining platform. 
Dako Auto Stainer universal platforms were used for staining, Dako REAL detection kit 
(K5001) was used for staining and visualising: Primary antibody (p53, ER or PR) 
staining was done for 1 hour, then rinsed with buffer, stained again with Chemate 
secondary antibody for 20 minutes, then rinsed again in buffer. Then a HRP blocking 
solution (DAKO, S2023) was applied for 10 minutes and then rinsed in buffer again. 
This was followed by staining with Chemate B tertiary biotinylated reagent for 20 
minutes and the rinsed in buffer. Visualisation was conducted with DAB for 10 minutes, 
the rinsed with deionised water with 0.1% tween. Regressive Harris Haematoxylin 
(Lecia, 01560BBE) and Saturated Lithium Carbonate (BDH Chemicals) were used for 
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counterstaining and bluing nuclei respectively. All slides were then dehydrated in 2 
changes of 100% IMS and cleared in 2 changes of xylene. All slides were cover slipped 
using DPX (BDH Chemicals, Merck, US). 
 
2.5.3.3 Immunohistochemical staining of Her-2 
HER-2 expression was evaluated in an accredited laboratory. Tissue sections were 
deparaffinised followed by endogenous peroxidase activity blocking by 12 min 
incubation in 0.3% hydrogen peroxide. Non-specific binding sites were blocked by 10% 
normal goat serum. Undiluted primary HER2-antibody (clone SP3, DCS-System, 
Hamburg) was applied on the sections and incubated for 90 minutes at room 
temperature. A streptavidin–biotin–peroxidase complex technique (Thermo Scientific 
Lab Vision, Fremont, USA) was used, and visualisation rendered with 3.3′-
diaminobenzidine tetrahydrochloride chromogen solution (Lab Vision, Thermo 
scientific, Fremont, USA). Sections were then counterstained with haematoxylin, and 
cover slipped. All immunostainings were performed manually and run with HER-2 
positive and negative breast cancer cell cultures included as controls. 
 
2.5.3.4 Haematoxylin and Eosin (H&E) staining 
H&E staining of sections was carried out by the Department of Pathology, Queen 
Elizabeth Hospital Birmingham. The department’s automated system was used to 
ensure consistency of staining. 
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2.5.4 Evaluation and scoring of immunohistochemistry 
Positive staining for CD 151 was defined by crisp cytoplasmic and partly membranous 
staining. Positive Clusterin staining was defined as unequivocal cytoplasmatic staining 
with or without membranous co-staining. ER and PR immunohistochemistry was 
deemed positive when there was clear nuclear staining. Positive p53 staining was 
characterised by unequivocal strong nuclear staining. Positive Her2 staining was 
characterised by clear membranous staining.  
Immunohistochemical staining intensity of all markers were evaluated independently, 
using light microscopy at x400 magnification blinded to the data and cross verified by 2 
pathologists. In the event of intra-observer or inter-observer variation a consensus score 
was decided on after examination by both observers at a multi-headed microscope. The 
IHC assays for Clusterin, CD151, ER, PR and p53 were scored in a semi-quantitative 
fashion incorporating both the intensity and the distribution of specific staining. The 
staining intensity (I) was graded as 0 (no staining), 1 (weak), 2 (moderate), or 3 (strong) 
after which the proportion of cells (P = 0-100%) for each observed staining intensity 
was recorded. A score (histologic or H-score = H) for each defined histologic category 
was determined as the product of the intensity and proportion using the formula (H = I × 
P) as given.229 230 H-score = (1x % of cells stained at intensity category 1) + (2x % of 
cells stained at intensity category 2) + (3x % of cells stained at intensity category 3). A 
H-score between 0 and 300 was obtained where 300 was equal to 100% of tumour cells 
stained strongly (3+). A H-score ≥150 was considered positive for the above markers.  
Her-2 scores were evaluated by a pathologist (G.S.) experienced at scoring Her2 who 
scored for intensity of staining compared to the negative control. Negative results were 
recorded for cases meeting one of the three following criteria: no staining, score 0; 
 101 
 
staining but without a membranous pattern, score 0; or incomplete membranous staining 
or complete membranous staining in less than 10% of the tumour cells, score 1. Positive 
results were recorded for cases meeting one of the two following criteria: complete 
membranous staining in greater than 10% of the tumour cells of moderate intensity, 
score 2, or complete membranous staining in greater than 10% of the tumour cells of 
strong intensity, score 3. 231  
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2.6 Statistical Analysis  
 
Fisher’s exact test was used for the association analyses of tumour types or stages with 
the proportion of positive expression of ER, PR or p53. Survival data were analyzed 
with Kaplan–Meier estimator and the Cox proportional hazards model. A Z-test was 
used to test the statistical significance of each coefficient in the model. Deaths due to 
cause other than endometrial cancer were excluded from the analyses of DSS or PFS. 
All statistical analyses were carried out using R (http://www.r-project.org/). The two-
sided p-values of less than 0.05 were considered statistically significant.  
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2.7 Adherence to reporting recommendations 
for tumour marker studies  
 
The “REMARK” criteria of the National Cancer Institute were used in design, analysis 
and interpretation of this research.232 These criteria are a collection of key reporting 
recommendations for tumour marker prognostic studies (See Table 2.2 on page 104). At 
the First International Meeting on Cancer Diagnostics in 2000 of the National Cancer 
Institute – European Organisation for Research and Treatment of Cancer (NCI–
EORTC) the development of such guidelines for the reporting of tumour marker studies 
was a major recommendation as a response to a widely recognized phenomenon and 
problem: When looking at the large number of tumour markers discovered over the 
years only very few reached a stage of clinical usefulness. Inconsistency of results and 
subsequent conclusions drawn from different studies of the same marker is one of the 
key problems. In order to improve understanding, comparability and reproducibility of 
such studies it was thought necessary not only to standardize details and quality of trials 
conducted in view of study design, pre-planned hypotheses, patient and specimen 
characteristics, precise assay methods, and statistical analysis methods but also to set 
standards on the presentation of data and rigor of reporting in published articles. The 
REMARK’s criteria as tabled below have been published by the cited author. The free 
full text of the original article can be accessed via the British Journal of Cancer. The 
criteria are listed in such a way that they function as a guide or line along which 
research groups may plan, conduct, revise and publish their data in a reproducible and 
transparent structure. This study has endeavoured to adhere to and conform with each 
REMARK criterion as a reference point of good quality. 
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Table 2.2 
REMARK CRITERIA 
Introduction  
 1. State the marker examined, the study objectives, and any prespecified hypotheses. 
  
Materials and Methods  
 Patients  
  2. Describe the characteristics (e.g. disease stage or comorbidities) of the study patients, including their source and 
inclusion and exclusion criteria. 
  3. Describe treatments received and how chosen (e.g. randomised or rule-based). 
  
 Specimen characteristics  
  4. Describe type of biological material used (including control samples), and methods of preservation and storage. 
  
 Assay methods  
  5. Specify the assay method used and provide (or reference) a detailed protocol, including specific reagents or kits 
used, quality control procedures, reproducibility assessments, quantitation methods, and scoring and reporting 
protocols.  
  
 Study design  
  6. State the method of case selection, including whether prospective or retrospective and whether stratification or 
matching (e.g. by stage of disease or age) was employed. Specify the time period from which cases were taken, the 
end of the follow-up period, and the median follow-up time. 
  7. Precisely define all clinical end points examined. 
  8. List all candidate variables initially examined or considered for inclusion in models. 
  9. Give rationale for sample size 
  
 Statistical analysis methods  
  10. Specify all statistical methods, including details of any variable selection procedures and other model-building 
issues, how model assumptions were verified, and how missing data were handled. 
  11. Clarify how marker values were handled in the analyses; if relevant, describe methods used for cutpoint 
determination. 
  
Results 
 Data  
  12. Describe the flow of patients through the study, including the number of patients included in each stage of the 
analysis (a diagram may be helpful) and reasons for dropout. Specifically, both overall and for each subgroup 
extensively examined report the numbers of patients and the number of events. 
  13. Report distributions of basic demographic characteristics (at least age and sex), standard (disease-specific) 
prognostic variables, and tumour marker, including numbers of missing values. 
  
 Analysis and presentation  
  14. Show the relation of the marker to standard prognostic variables. 
  15. Present univariate analyses showing the relation between the marker and outcome, with the estimated effect 
(e.g. hazard ratio and survival probability). Preferably provide similar analyses for all other variables being 
analysed. For the effect of a tumour marker on a time-to-event outcome, a Kaplan–Meier plot is recommended. 
  16. For key multivariable analyses, report estimated effects (e.g. hazard ratio) with confidence intervals for the 
marker and, at least for the final model, all other variables in the model. 
  17. Among reported results, provide estimated effects with confidence intervals from an analysis in which the 
marker and standard prognostic variables are included, regardless of their significance. 
  18. If done, report results of further investigations, such as checking assumptions, sensitivity analyses, internal 
validation. 
  
Discussion  
 19. Interpret the results in the context of the prespecified hypotheses and other relevant studies; include a discussion 
of limitations of the study. 
 20. Discuss implications for future research and clinical value. 
Table of reporting recommendations for tumour marker prognostic studies 
(REMARK) by L.M. Mc Shane. 232
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CHAPTER 
3 RESULTS 
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3.1 Patient characteristics 
 
156 patients fitting into the inclusion criteria were treated between 01.01.1997-
31.12.2002. Clinical and pathological features are summarised in Table 3.1 (see page 
108). A mean patient age of 68.2 years (range, 37 to 89) was noted. Histology showed 
76 cases (48.7%) with grade 3 endometrioid carcinoma, 32 (20.5%) with UPSC, 9 
(5.8%) with CC, 18 (11.5) with sarcoma, 13 (11.5%) with MMMT and 4 (2.6%) with 
mixed epithelial tumour of the uterus. 87 cases (55.77%) were diagnosed at FIGO stage 
I, 14 (8.97%) at stage II, 35 (22.4%) at stage III and 20 (12.8%) at stage IV. According 
to FIGO, myometrial invasion less than 50% without any disease elsewhere is staged 
IA. 58 cases (37.2%) showed <50% myometrial invasion, 94 cases (60.3%) showed 
≥50% (Table 3.1, see page 108).  
Over 85.9% (134) of patients underwent total abdominal hysterectomy with bilateral 
salpingo-oophorectomy and peritoneal washings. In 32 cases (20.51%) a bilateral pelvic 
lymphadenectomy was performed taken against 124 (79.49%) in which this was not 
done. This was consistent with surgical practice in the United Kingdom, in the study 
time period. Patients without gross peritoneal disease and lymphadenectomy were 
staged according to the extent of uterine involvement.  
Platinum based chemotherapy or pelvic radiation was given at the discretion of the local 
MDT recommendation. No patient received chemotherapy or radiotherapy before 
surgery. Of the patients who did receive follow-up treatment, 41% received external-
beam radiation therapy (EBRT) or brachytherapy alone, 14.7% received chemotherapy 
alone, 3.2% received EBRT plus chemotherapy, and 55.1% received no additional 
therapy beyond surgical resection. Seventy-eight patients died during the observation 
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period, 60 related to endometrial cancer and 18 related to other causes. 64 adverse 
events were recorded, which included recurrent disease as well as deaths related to 
endometrial cancer.  
 
3.2 Data complete for analysis 
 
Of the 156 patients included in this study, 131 patients (83.97%) had archived paraffin 
embedded tissue and complete follow-up data available for analysis. Of the 25 cases 
lost, for 19 patients the archived tissue blocks could not be retrieved or tumour material 
received, in 3 patients TMA cores were lost or were judged insufficient to analyse and 3 
patients were lost from the system during the observation period. 
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Table 3.1 
PATIENT CHARACTERISTICS PATIENTS (N = 156) 
  
Age, mean (range) 68.2 (56,8-79,6) 
  
FIGO stage, n (%)  
I 87 (55.77) 
II 14 (8.97) 
III 35 (22.4) 
IV 20 (12.8) 
  
Histologic type, n (%)  
EEC 78 (50.0) 
UPSC 33 (21.15) 
Clear Cell 9 (5.8) 
MMMT 18 (11.54) 
Sarcoma 14 (8.97) 
Mixed histology 4 (2.6) 
  
Myometrial invasion, n (%)  
≤50% 58 (37.2) 
>50% 94 (60.3) 
Missing 4 
  
Hysterectomy  
Yes 134 (85.9) 
No 22 (14.1) 
  
Lymphnodes  
Taken 32 (20.51) 
Not taken 124 (79.49) 
  
Chemotherapy, n (%)  
Yes  28 (17.9) 
No 128 (82.1) 
  
Radiotherapy, n (%)  
Yes 64 (41.0) 
No 92 (59.0) 
  
Outcome  
Alive without disease 73 (46.8) 
Alive with disease 4 (2.6) 
Died of disease 61 (39.1) 
Death of other causes 18 (11.5) 
  
Observation time 148 months 
  
Complete data for analysis 131 (83.97%) 
Lost for follow-up or missing tissue-samples 25 (16.03%) 
Clinicopathological data of base cohort. 
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3.3 Formation of histology groups I, II and III 
 
Partly due to the small numbers found for some of the tumours and also to aid analysis 
of outcome three histological groups were formed:  
 
Group I = G3 endometriod (G3 EEC);  
Group II = UPSC + CC (UPSC+CC); 
Group III = sarcoma + MMMT + mixed histology (Sarcoma+MMMT+mixed). 
 
Results for a subgroup “triple negative” were also analysed which included all cases 
where ER, PR and Her-2 expression was rated negative. The purpose of this grouping 
was to compare CD151 performance with findings in breast cancer tissue.189 Due to the 
fact that group III is histologically and clinically an altogether different group in 
comparison to the two types of endometrial carcinoma it was decided to present the 
marker expression and survival data of group III separately from those of group I and II. 
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3.4 Marker Expression of group I and II 
 
A detailed analysis of CD151, Clusterin, p53, ER, PR and Her2 expression by stage and 
the histology groups I and II are presented in Table 3.2 below. 
Table 3.2 
 PATIENTS  
(TOTAL=131)  
N 
CD151  
 
N, % 
CLUSTERIN 
 
N, % 
ER 
 
N, % 
PR 
 
N, % 
P53 
 
N, % 
HER2 
 
N, % 
Stage 
       
I 71 45 (63.3) 38 (53.52) 12 (16.90) 6 (8.45) 15 (21.12) 3 (4.22) 
II 14 5 (35.7) 5 (35.71) 2 (14.3) 0 3 (21.4) 2 (14.3) 
III 28 12 (42.8) 14 (50.0) 3 (10.7) 2 (7.1) 9 (32.1) 1 (3.6) 
IV 18 10 (55.5) 9 (50.0) 4 (22.2) 2 (11.1) 4 (22.2) 2 (11.1) 
Histology 
       
EEC 68 25 (36.76) 31 (45.59) 15 (22.06) 3 (4.4) 13 (19.1) 3 (4.4) 
UPSC 31 30 (96.7) 19 (61.29) 6 (19.4) 4 (12.9) 11 (35.4) 4 (12.9) 
CC 7 7 (100) 4 (57.14) 0 1 (14.3) 1 (14.3) 1 (14.3) 
Sarcoma 13 4 (30.8) 7 (53.85) 0 0 5 (38.5) 0 
MMMT 9 1 (11.1) 5 (55.56) 0 2 (22.2) 0 0 
Mixed histology 3 0 0 0 0 1 (33.3) 0 
UPSC+CC 38 37 (97.4) 23 (60.53) 6 (15.8) 5 (13.2) 12 (31.6) 5 (13.2) 
Sarcoma+ 
MMMT+mixed 
25 5 (20) 12 (48.0) 0 2 (8) 6 (24) 0 
Outcome 
       
Alive without disease 53 32 (60.3) 26 (49.07) 9 (17) 4 (7.5) 11 (20.8) 2 (3.8) 
Alive with disease 5 3 (60) 3 (60.0) 1 (20) 0 0 0 
Died of disease 56 22 (39.3) 27(48.21) 8 (14.3) 4 (7.1) 15 (26.8) 4 (7.1) 
Died of other causes 17 10 (58.8) 10 (58.82) 3 (17.6) 2 (11.8) 5 (29.4) 2 (11.8) 
Marker positivity in relation to clinicopathological features. Positive CD151-, Clusterin-, 
ER-, PR- and p53-immunhistochemistry mean H-scores are greater than 150; Her2-
positive IHC means a value of greater than 1. Abbreviations: EEC, endometrioid 
endometrial Carcinoma, UPSC, uterine papillary serous carcinoma; CC, clear cell 
carcinoma; MMMT, malignant mixed muellerian tumour.  
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3.4.1 Expression of CD151 
Figure 3.2 (next page) shows immunohistochemical staining with antibody to CD151. 
Staining was predominantly cytoplasmic with regions of membranous accentuation. 
Some tumours showed absent (score 0-50, see Fig.3.2, A on page 125) or only modest 
CD151 expresssion (score 51-150, see Fig. 3.2, B on page 125), others showed 
moderate to high CD151 (score 151-300, see Fig. 3.2, C on page 125). CD151 showed 
no specific association with tumour stages. CD151 marker positivity within the tumour 
stages among the entire cohort ranged between 35.71% (stage II) and 63.38% (stage I), 
with stage III and IV showing 42.86% and 55.56% marker positivity for CD151 (Table 
3.2, see page 110).  
 
Figure 3.1 
 
Box plot of H-sores expression pattern of CD151 within the histological groups. 
There is a significant difference in CD151 expression between histo-group 1 and 2 
(P-value of Mann-Witney test < 0,00082), between histo-group 2 and 3 (P-value of 
Mann-Witney test < 0,00079) and border line between histo-group 1 and 3 (P-value 
of Mann-Witney test = 0.04106). 
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Figure 3.2 
  
  
 
Staining intensities of CD151: A, weak staining (H-score 0-50), endometrioid 
endometrial carcinoma; B, moderate staining (H-score 51-150), uterine sarcoma; 
C, strong staining (H-score 151-300), uterine papillary serous carcinoma.  
 
 
 
A 
B 
C 
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CD151 scored positive in 98.5% of UPSC+CC (group II) cases, whilst in G3 EEC cases 
(group I) this was in less than 50%. CD151 expression was significantly raised in 
UPSC+CC tumour types compared with lower expression in G3 EEC (p <0.001). 
(Figure 3.1, see page 111 and Table 3.2, see page 110) 
The highest proportion of CD151 expression was found in ‘‘triple-negative’’ (oestrogen 
receptor-, progesterone receptor-, and HER2-negative) tumours. In the triple negative 
subgroup CD151 expression was significantly higher compared to the rest of the cohort 
(p <0.001).  
In univariate analyses CD151 had a significant influence in overall- (OS), disease 
specific- (DSS) and recurrence free survival (RFS) (p = 0.04, 0.02 and 0.02 
respectively) (Table 3.5, see page 126). In multivariate analyses this influence was not 
significant (Table 3.6, see page 127). For the triple negative cohort (n=88) however, 
CD151 expression showed a significant influence in overall- (OS), disease specific- 
(DSS) and recurrence free survival (RFS) in uni- and multivariate analysis (Table 3.5. 
and 3.6, see pages 126 and 127 respectively).  
Interestingly, this study revealed an inverse correlation of CD151 expression and 
survival. Whether in the UPSC+CC histology group or the “triple-negative” group, a 
higher expression correlated significantly with improved survival. (Figure 3.3, see page 
114) 
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Figure 3.3 
    
Kaplan-Meier curve of CD151 expression in relation to survival. Left: Overall 
Survival. The hazard ratio between the two CD151 groups (67 CD151 H-score 
greater than median and 64 CD151 H-score less than median) is 1.595 (95% 
confidence interval 1.003 to 2.538), p-value = 0.04674, indicating that there is 
significant difference in survival between the two groups.  
Right: The hazard ratio between the two CD151 groups is 1.816 (95% confidence 
interval 1.060 to 3.109), p-value = 0.02746, indicating that there is significant 
difference in disease specific survival between the two groups. 
 
 
Kaplan Meier curve of CD151 expression in relation to survival in the triple 
negative group (ER, PR and Her2 negative). Left: Overall Survival. The hazard 
ratio between the two CD151 groups (49 CD151 H-score greater than median and 
52 CD151 H-score less than median) is 2.235 (95% confidence interval 1.289 to 
3.87), p-value = 0.003289) indicating that there is significant difference in survival 
between the two groups.  
Right: Disease Specific Survival. The hazard ratio between the two CD151 groups 
is 2.940 (95% confidence interval 1.505 to 5.741), p-value = 0.0009411, indicating 
that there is significant difference in survival between the two groups.  
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3.4.2 Expression of Clusterin (Clu)  
Figure 3.4 (next page) shows immunohistochemistochemical staining with antibody to 
Clusterin. Clusterin marker positivity within the tumour stages among the entire cohort 
ranged between 35.71% (stage II) and 53.52% (stage I), with stage III and IV both 
showing 50% marker positivity for Clusterin (Table 3.2, see page 110).  
Regarding expression levels within the 3 tumour groups, Clusterin expression was 
45.59% in G3 EEC against 60.53% in UPSC+CC (p=0.102). (Table 3.3, see page 121). 
Clusterin receptor expression had no significant influence on survival in the univariate 
analysis (Figure 3.5, see page 117). Clusterin was expression was often detected in 
necrotic cells, which may be indicative of its role in the regulation of apoptosis. 
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Figure 3.4 
 
 
 
 
 
 
Staining intensities of Clusterin: A, weak staining (H-score 0-50), MMMT; B, 
moderate staining (H-score 51-150), uterine papillary serous carcinoma; C, strong 
staining (H-score 151-300), G3 endometrioid endometrial carcinoma.  
A 
B 
C 
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Figure 3.5 
 
 
Kaplan-Meier curve of Clusterin expression in relation to survival. Top: Overall 
Survival. The hazard ratio between the two CLU groups (66x CLU H-score greater 
than median and 65x CLU H-score less than median) is 1.030 (95% confidence 
interval 0.6507 to 1.630), p-value = 0.9003) indicating that there is no significant 
difference in survival between the two groups.  
Bottom left: Disease Specific Survival. The hazard ratio is 1.096 (95% confidence 
interval 0.6488 to 1.852), p-value = 0.7316 indicating that there is no significant 
difference in disease specific survival between the two groups.  
Bottom right: Progression Free Survival. The hazard ratio is 1.067 (95% 
confidence interval 0.646 to 1.764), p-value = 0.7991) indicating that there is no 
significant difference in progression free survival between the two groups.  
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3.4.3 Expression of Oestrogen Receptor (ER) and  
Progesterone Receptor (PR) 
Figure 3.6 (see next page) shows immunohistochemical staining with antibody to ER 
and PR.  
ER marker positivity within the tumour stages among the entire cohort ranged between 
10.71% (stage III) and 22.22% (stage IV) – in stage I ER positivity was 16.9%. PR 
expression within the tumour stages expression ranged between 7.14% (stage III) and 
11.14% (stage IV) (Table 3.2, see page 110).  
Within the tumour groups, 22.06% of G3 EEC expressed ER compared to 15.79% 
expressed by the UPSC+CC group (p=0.612). (Table 3.3, see page 121). ER and PR 
receptor expression had no significant influence on survival in the univariate analysis 
(Table 3.5, see page 126). 
 
3.4.4 Expression of p53 
Figure 3.6 (see next page) shows immunohistochemistochemical staining with antibody 
to p53. P53 marker positivity within the tumour stages among the entire cohort ranged 
between 21.13% (stage I) and 32.19% (stage III) (Table 3.2, see page 110). The highest 
expression rate was reached by p53 with 31.6% in the UPSC+CC group compared to 
19.1% in the G3 EEC group (p=0.16) (Table 3.3, see page 121). P53 receptor 
expression had no significant influence on survival in the univariate analysis (Table 3.5, 
see page 126). 
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3.4.5 Expression of Her-2 
Figure 3.6 (see below) shows immunohistochemistochemical staining with antibody to 
Her-2. Her-2 positivity (>1) was seen in only 8(6.11%) of all cases in the tissue 
microarray. Her-2 marker positivity within the tumour stages among the entire cohort 
ranged between 3.57% (stage III) and 14.29% (stage II) (Table 3.2, see page 110). The 
highest expression of Her-2 was observed in the UPSC+CC group with 13.16% 
compared to 4.41% in the G3 EEC group (p=0.132) (Table 3.3, see page 121). Her-2 
receptor expression had no significant influence on survival in the univariate analysis 
(Table 3.5, see page 126). 
 
 
Figure 3.6 
 
Immunohistochemistry in G3 EEC tumours (1a-d) and UPSC tumours (2a-d) with 
antibodies against p53 (a), Her-2 (b), ER (c), PR (d) at high power ×100 
magnification. 
 
1a 1b 1c 1d 
2a 2b 2c 2d 
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3.5 Comparison of results between G3 EEC 
(group I) and UPSC+CC (group II)  
 
Table 3.3 on page 121 demonstrates tumour stage at diagnosis for group I and II. More 
patients with UPSC+CC were found to have stage III- and IV-disease at diagnosis 
compared with the G3 EEC group but differences were not statistically significant 
(44.74% vs. 30.88%, p=0.384). 
When looking at myometrial invasion at the time of initial surgery, again there was no 
significant difference - whilst 32(47.06%) G3 EEC tumours showed >50% myometrial 
invasion there were 20(52.63%) cases in the UPSC+CC group (p = 0.707). For ER, PR, 
p53 and Her2 expression, there was also no significant difference in marker positivity 
between the two histological groups. 
Survival data between group I and II were very similar. Table 3.4 (see page 124) shows 
survival outcome of the 2 histological groups within the observation time/follow-up 
period of 148 months and a range of 0.1 to 11.7 years. Group I and II showed an almost 
identical disease specific survival (DSS) with 4.6 (G3 EEC, range 0.01-11.79) and 4.7 
(UPSC+CC, range 0.07-10.33) years (p<0.001) and similar proportions of patients in 
each group died of their disease or of other causes (data not shown). Figure 3.7 (see 
page 122) shows the Kaplan-Meier curves for disease specific and recurrence free 
survival of group I and II in this study group. 
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Table 3.3 
 
ALL 
PATIENTS  
N (%) 
GROUP I  
(ECC) 
N (%) 
GROUP II 
(UPSC+CC) 
N (%) 
 
P – VALUE 
N 131 68 38  
Mean age 
at diagnosis 
67.98 68.01 67.08 0.697 
Stage I 71 (54.20) 42 (61.76) 17 (44.75) 
Stage II 14 (10.69) 5 (7.35) 4 (10.53) 
Stage III 28 (21.37) 13 (19.12) 11 (28.95) 
Stage IV 18 (13.74) 8 (11.76) 6 (15.79) 
0.384 
Myometrial 
invasion ≥50% 
62(47.33) 32(47.06) 20(52.63) 0.707 
ER 
positive IHC  
(i.e. >150) 
21 (16.03) 15 (22.06) 6 (15.8) 0.612 
PR 
positive IHC  
(i.e. >150) 
10 (7.63) 3 (4.4) 5 (13.2) 0.132 
P53 
positive IHC  
(i.e. >150) 
31 (23.66) 13 (19.1) 12 (31.6) 0.16 
Her2 
positive IHC 
(i.e.>1) 
8 (6.11) 3 (4.4) 5 (13.2) 0.132 
CD151 
positive IHC 
(i.e.> median) 
109 (83.21) 25 (36.76) 37 (97.4) <0.0001 
Clusterin 
positive IHC 
(i.e.> median) 
66 (50.38) 31 (45.59) 23 (60.53) 0.144 
Comparison between histological groups I and II in view of clinicopathological  
features and marker expression. EEC, endometrioid endometrial carcinoma;  
UPSC, uterine papillary serous carcinoma; CC, clear cell carcinoma of the uterus;  
ER, estrogen receptor; PR, progesterone receptor. 
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Figure 3.7 
 
Kaplan-Meier curves of survival patterns of the 3 histological groups. “Endo” = 
Group I (G3 EEC); “upsc and clear cell” = Group II; “rest” = Group III 
(Sarcoma+MMMT+ mixed).  
Left graph: Disease specific survival; the hazard ratio between the "upsc and clear 
cell" and “endo” group is 1.069 (95% confidence interval 0.553 to 2.067, p-value = 
0.84233). The hazard ratio between the “rest” and “endo” group is 2.926 (95% 
confidence interval 1.583 to 5.406, p-value = 0.00061).  
Right graph: Progression free survival; The hazard ratio between the "upsc and 
clear cell"and “endo” group is 1.056 (95% confidence interval 0.5686 to 1.960,  
p = 0.86380). The hazard ratio between the “rest” and “endo” group is 2.577 (95% 
confidence interval 1.4164 to 4.690, p = 0.00194). 
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3.6 Survival Analysis of G3 EEC (group I) and   
UPSC+CC (group II) 
 
Study enrolment and data collection for this study commenced in 1997. Whilst patient 
recruitment stopped in 2002 follow-up continued until May 1st, 2010. Thus follow-up 
time ranged between 88 months (7 years, 4 months) and 160 months (13 years, 4 
months). 
The mean all-stage-, all-histology- overall survival (OS) was 4.01 years (range  0.01-
11.79yrs), disease specific survival (DSS) (114 of 131) was 4.267 years (range 0.01-
11.79) and recurrence free survival (RFS) (114 of 131) was 4.108 years (range 0.01-
11.79). Patients with low stage (I-II) had a DSS of 5.318 years whilst patients with 
advanced stage (III-IV) lived significantly shorter with a DSS of 2.24 years (Hazard 
ratio 4.373 (CI 2.55-7.49) p <0.001) (Table 3.4, see page 124). The mean follow-up 
time was 4.01 years (range, 0.01 – 11.79 years). 
The Kaplan-Meier curves for disease specific and recurrence free survival of group I 
and II (Figure 3.7, see page 122) demonstrate the similar the survival patterns between 
these two groups.  
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Table 3.4 
 N MEAN MIN – MAX 
All patients     
OS  131(100) 4.01 0.01-11.79 
DSS 114(87.02) 4.267 0.01-11.79 
RFS 114(87.02) 4.108 0.01-11.79 
G3 EEC histology (group I) 
   
OS 68(59.65) 4.375 0.01-11.79 
DSS  59(45.04) 4.618 0.01-11.79 
RFS  59(45.04) 4.409 0.01-11.79 
UPSC+CC histology (group II) 
   
OS 38(29.01) 4.26 0.07-10.33 
DSS 32(24.43) 4.716 0.07-10.33 
RFS 32(24.43) 4.567 0.07-10.33 
Sarcoma+MMMT+ mixed 
(group III) 
   
OS 25(19.08) 2.639 0.05-11.43 
DSS  23(17.56) 2.743 0.05-11.43 
RFS  23(17.56) 2.698 0.05-11.43 
Stage I-II 
   
OS  85 (64.88) 5.05 0.05-11.79 
DSS  75 (57.25) 5.318 0.05-11.79 
RFS 75 (57.25) 5.108 0.05-11.79 
Stage III-IV 
   
OS  46 (35.11) 2.09 0.01-11.43 
DSS  39 (29.77) 2.247 0.01-11.43 
RFS 39 (29.77) 2.185 0.01-11.43 
Mean survival within the 3 histology groups and according to tumour stage. OS,  
overall survival; DFS, disease-free survival; RFS, recurrence-free survival. 
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3.6.1 Univariate Analysis 
For the histology groups I and II in univariate analyses age, stage, CD 151 were 
significant factors impacting on DSS and RFS (Table 3.5, see page 126). Low CD151 
expression was associated with significantly worse DSS (Hazard ratio (HR) 1.816, p = 
0.02) and RFS (HR 1.773, p = 0.02) when compared to strong expression. Her2, ER, PR 
and p53 expression were not significantly associated with survival. In univariate 
analysis CD151 expression in the triple negative (ER, PR and Her2-negative) subgroup 
(n=88) was even stronger associated with reduced DSS (HR 2.94, p <0.001) and RFS 
(HR 2.54, p <0.001) compared to the entire cohort.  
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Table 3.5. 
 OVERALL SURVIVAL 
(OS) 
DISEASE SPECIFIC SURVIVAL  
(DSF) 
PROGRESSION-FREE SURVIVAL 
(PFS) 
 Hazard 
Ratio 
95% CI p Hazard Ratio 95% CI p Hazard Ratio 95% CI p 
Stage 
 
         
I+II Ref.   Ref.   Ref.   
III+IV 3.899 2.43 – 6.24 <0.001 4.373 2.55 – 7.49 <0.001 3.965 2.37 – 6.62 <0.001 
Histo type 
 
         
ECC Ref   Ref   Ref   
UPSC+ 
CC 
1.105 0.63 – 1.92 0.72 1.069 0.55 – 2.067 0.84 1.056 0.56 – 1.96 0.86 
Sarc+ MMMT 
+ mixed 
2.518 1.44 – 4.40 0.001 2.926 1.58 – 5.40 <0.001 2.577 1.41 – 4.69 0.001 
Markers 
 
         
Clusterin 
(below/  
above median 
1.03 0.65 – 1.63 0.900 1.096 0.64 – 1.85 0.731 1.067 0.64 – 1.76 0.799 
CD151 
(below/ 
above median) 
1.595 1.00 – 2.53 0.04 1.816 1.06 – 3.10 0.02 1.773 1.06 – 2.96 0.02 
Her2 
(0-1/2-3) 
1.500 0.64 – 3.461 0.338 1.541 0.55 – 4.26 0.402 1.408 0.51 – 3.88 0.506 
P53 
<150/≥150 
1.125 0.74 – 2.09 0.391 1.283 0.71 – 2.32 0.409 1.112 0.62 – 1.99 0.72 
ER 
<150/≥150 
0.806 0.42 – 1.53 0.511 0.815 0.38 – 1.72 0.591 0.851 0.419 – 1.72 0.655 
PR 
<150/≥150 
0.938 0.40 – 2.165 0.881 0.962 0.34 – 2.66 0.94 0.864 0.31 – 2.38 0.77 
CD151 (in triple 
negative group) 
(below/above 
median  
2.235 1.28 – 3.87 0.003 2.94 1.50 – 5.74 <0.001 2.541 1.37 – 4.71 0.008 
Univariate survival analysis. Note: Analysis of age was performed in a linear fashion; thus, there is no referent variable. 
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3.6.2 Multivariate Analysis 
In multivariate analyses age, stage and tumour type maintained significance. CD151 
maintained prognostic significance for the triple negative subgroup (DSS, p=0.033, 
RFS, p=0.036) but not for the entire cohort (see Table 3.6 below). ER, PR, p53 and 
Her2 were not significant factors influencing survival. 
 
Table 3.6 
 DSS – SURVIVAL PF-SURVIVAL 
 
Hazard 
Ratio 
OR – 95%CI p-value 
Hazard  
Ratio 
OR – 95%CI p-value 
Age 1.0600 
1.0335 -    
1.087 
<0.001 1.0595 
1.0343 -     
1.085 
<0.001 
Stage III or IV 5.0119 
2.8090 -   
8.942 
<0.001 4.5366 
2.6132 -    
7.876 
<0.001 
UPSC+CC 1.0603 
0.4215 -    
2.667 
n.s. 1.0757 
0.4534 -   
2.552 
n.s. 
Sarcoma+MMMT 2.7967    
1.3878 -  
5.636 
0.004 2.4431 
1.2438 -     
4.799 
0.0095 
CD151  
(below median) 1.4304 
0.6424 -     
3.185 
n.s. 1.5535   
0.7332 -  
3.292 
n.s. 
ER 
(above median) 0.9980   
0.9920 -     
1.004 
n.s. 0.9997    
0.9946 -     
1.005 
n.s. 
PR 
(above median) 1.0006   
0.9938 -     
1.008 
n.s.  0.9988 
0.9923 -     
1.005 
n.s. 
P53 
(above median) 0.9991 
0.9949 -     
1.003 
n.s. 0.9983   
0.9943 -    
1.002 
n.s. 
Her2 
(above median) 1.5916 
0.5307 -     
4.773 
n.s. 1.5389   
0.5179 -     
4.573 
n.s. 
CD151  
(in triple negative 
pts.) 
3.168 
1.1005 - 
9.123 
0.033 2.792 
1.0682 –
7.299 
0.036 
CD151 
below median 
3.168 
1.1005 -   
9.123 
0.003 2.792 
1.0682 -    
7.299 
0.003 
Multivariate survival analysis for disease-free-survival (DSS) and progression-free-
survival (PFS). N.s., not significant. 
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3.7 Marker Expression in group III 
(Sarcoma+MMMT+mixed histology) 
 
3.7.1 Expression of CD151 
Whilst CD151 in UPSC+CC cases scored positive in 98.5% it was less than 50% in the 
G3 EEC and Sarcoma+MMMT+mixed group. CD 151 expression was significantly 
raised in UPSC+CC tumour types compared with lower expression in 
Sarcoma+MMMT+mixed histology group (p <0.001) (Table 3.2, see page 110). 
 
3.7.2 Expression of Clusterin (Clu)  
In group III positive Clusterin expression was 48% which was just above that of G3 
EEC (45.59%) and below the value for UPSC+CC (60.53%) (Table 3.2, see page 110).  
 
3.7.3 Expression of Estrogen Receptor (ER) and  
Progesterone Receptor (PR) 
In group III there was no positive ER expression. PR expression behaved similar 
(p=0.132) (Table 3.2, see page 110).   
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3.7.4 Expression of p53 
 Marker positivity in group III was 24%. This was insignificantly less than the 
expression rate for the UPSC+CC group (31.6%) and the G3 EEC group (19.1%) (Table 
3.2, see page 110). 
 
3.7.5 Expression of Her-2 
No marker positivity was found in group III for Her-2 whilst in group I and II it was 
insignificantly higher with 4.41% and 13.16% respectively (Table 3.2, see page 110). 
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3.8 Survival Analysis for group III 
(Sarcoma+MMMT+mixed histology) 
 
3.8.1 Univariate Analysis 
In univariate analyses sarcoma/MMMT/mixed group was like age, stage and CD 151 a 
significant factor impacting on DSS and RFS (Table 3.5, see page 126).  
 
3.8.2 Multivariate Analysis 
In multivariate analyses the sarcoma/MMMT/mixed group maintained, together with 
age and stage, its statistical significance as a predictor for poor survival (Table 3.6, see 
page 127).  
 
3.8.3 Comparison of results between the histological groups 
There was a significant survival difference between group I and II versus group III.  
Table 3.2 (see page 110) shows stage at diagnosis for group I, II and III. Table 3.4 (see 
page 124) shows the survival outcome of the 3 histological groups within the 
observation time/follow-up period of 148 months and a range of 0.1 to 11.7 years.  
The Kaplan Meier curves of Figure 3.7 (see page 122) show a significantly shortened 
survival for group III in comparison with the other two groups. They demonstrate a 
disease specific survival of 2.7 years (0.05-11.43) in comparison with 4.6 (G3 EEC, 
range 0.01-11.79) and 4.7 (UPSC+CC, range 0.07-10.33) years (p<0.001).  
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CHAPTER 
4 DISCUSSION 
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4.1 Introduction 
 
This chapter discusses the results obtained in this thesis starting with an introduction 
into the study plan and the approach to novel biomarker testing. It will then summarise 
the results in a synopsis followed by a detailed discussion. 
The chapter will close with an attempt of critical consideration of methodological errors 
and other details which could have been done differently in the conduct of this study 
Finally, ideas of further studies will be outlined. 
 
In this study tumour tissue specimen and data of 156 patients diagnosed with poor 
prognosis endometrial cancer were collated. The tissue specimen obtained from these 
patients included grade 3 endometrioid endometrial carcinoma (G3 EEC), uterine 
papillary serous cancer (UPSC), clear cell carcinoma of the uterus (CC), malignant 
uterine tumours of mixed histology, uterine sarcoma and carcinosarcoma (MMMT). All 
patients were treated surgically and systematically according to International Federation 
of Gynaecology and Obstetrics (FIGO) guidelines. In the observation time of 148 
months clinicopathological- and survival data including tumour recurrence, disease 
progression and death were collected. Based on clinical considerations, partly due to the 
small numbers found for some of the tumours and also to aid analysis of outcome data 
were analysed within three histological groups: Group I = G3 endometrioid (G3 EEC); 
group II = UPSC + CC (UPSC+CC); group III = sarcoma + MMMT + mixed histology 
(Sarcoma+MMMT+mixed). From paraffin embedded tumour blocks of the collected 
tissue specimen 5 tissue microarray blocks were constructed to provide multiple tumour 
specimen ready for immunohistochemical analysis. 
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The aim of the study was to assess the prognostic significance of the novel marker CD 
151 as well as clusterin and compare them with clinicopathological data and other 
established markers (ER, PR, p53). A further aim was to compare 
immunohistochemistry profiles and survival outcome of grade 3 endometrioid cancers 
(G3 EEC) with type 2 cancers (UPSC+CC) of the cohort investigated. 
The strengths of this study are the long duration of follow-up and high numbers of poor 
prognostic types of tumours together with the thorough pathology review independently 
performed by 3 specialist gynaecological pathologists (RG, KM, and LL) and the 
robustness of follow-up ascertainment.  
The cohort includes G3 endometrioid endometrial cancers (G3 EEC) which are usually 
not included into type II endometrial cancers. However, they fit the criteria in so far as 
they demonstrate more aggressive behaviour and are of significantly poorer prognosis 
(58% 5year survival) than low grade endometrioid cancers.14 As mentioned above tissue 
cores were also collected from sarcomas, carcinosarcomas and uterine tumours of mixed 
histology (group III = Sarcoma+MMMT+mixed) which were included for the same 
reason – they are also of poor prognosis with currently no adjuvant treatment that has 
shown to clearly improve survival.233-238 Although the tissue set contained divergent 
histology types clinically these tumours result in poor outcome and justify being 
investigated together in the same TMA. 
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4.2 Synopsis of Results 
 
One of the main findings in this study was the clear demonstration that grade 3 
endometrioid endometrial carcinoma (G3 EEC, group I) and uterine papillary serous 
and clear cell carcinoma (UPSC+CC, group II) had very similar clinical, 
immunohistochemistry profiles and survival outcomes. This has been published recently 
in Gynecologic Oncology.239 Whilst novel at the time, this concept is becoming 
increasingly accepted and validated by international groups in this field. Data from The 
Cancer Genome Atlas consortium (TCGA) on genomic data from endometrial cancer 
also show that at least a proportion of grade 3 endometrioid cancers are ‘serous’ type 
and display molecular alterations that are very similar to serous cancer. The latest 
insights from TCGA data suggests that endometrial cancer is a continuum with well 
differentiated grade 1 endometrioid cancer on one end of the spectrum and serous 
cancer at the other end of the spectrum.52  
CD151 was identified in this study as an independent marker for disease specific and 
recurrence-free survival in poor outcome endometrial carcinoma by univariate analysis 
and for a triple negative subgroup of patients by multivariate analysis. The data indicate 
that CD151 is differentially expressed, with highest expression in the UPSC and CC 
histology types. Contrary to expectation based on published literature, high CD151 
expression was found to correlate positively with improved survival. Thus, this is the 
first report which suggests that expression of this tetraspanin protein in tumours may 
prevent transition to a malignant phenotype or, perhaps, preclude development of more 
malignant tumour types. These findings have been recently published in the British 
Journal of Cancer. 240 
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Clusterin expression throughout the cohort was positive between 48% and 60% in the 
three histological groups. Clusterin expression showed no significant correlation with 
survival. This is also the first study to evaluate the staining and prognostic significance 
of clusterin as a clinical marker in grade 3 endometrioid endometrial carcinoma.  
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4.3 Discussion of the findings between    
G3 EEC and UPSC+CC 
 
This is the first study to purposefully compare clinical and IHC parameters between G3 
EEC and UPSC+CC as well as other poor prognosis endometrial tumours and 
demonstrate survival outcome.239 
Investigating the clinicopathological features in the cohort of this study, there was no 
significant difference in the mean age of diagnosis or stage distribution at the time of 
initial treatment. In the stage distribution it is of note that 68% of G3 EEC was 
diagnosed in stage I and II. This is a considerably lower percentage in comparison to the 
commonly published figures that 85-90% of all endometrioid carcinomas are diagnosed 
at such early stages and highlights the need for research into early diagnosis and patient 
education.241 
UPSC and CC histologies have been shown to result in different clinical outcomes 
compared to all endometrioid histology with extrauterine spread of disease more 
common, and survival outcomes poorer than in EEC.59 However, comparing UPSC+CC 
cases specifically with G3 EEC cases in this study, Kaplan-Meier curves demonstrate 
that the overall - , disease free -  and recurrence-free survival is similar. These findings 
are consistent with McMeekin and his co-workers in a large GOG-study investigating 
1203 patients with advanced/recurrent endometrial cancer treated with chemotherapy.242  
One possible criticism of our study is the incompleteness of what would be considered 
optimal staging for these cancers today. Current management for UPSC and CC 
carcinoma includes omental biopsy in recognition of greater systemic spread with these 
cancers. Whilst randomised controlled trials of lymphadenectomy in endometrial cancer 
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have demonstrated no survival benefit, systematic pelvic and para-aortic 
lymphadenectomy can help accurate staging and guide adjuvant therapy. However, 
clinical management in this study was consistent with standard practice of its era and 
compliant with the protocol for the ASTEC trial.76 The time period of the study was 
selected to enable a long duration of follow-up. Given that this study compares all stage, 
disease specific survival and recurrence free survival between the two groups, it is 
believed that understaging in both groups is unlikely to alter the findings of the study.239 
 
ER and PR expression are known to be common in well-differentiated endometrioid 
endometrial carcinomas and their presence may confer a survival benefit in comparison 
to ER/PR negative tumours.243 Hormone receptor positivity is used to guide 
management in women with endometrial cancers, particularly at recurrence, with the 
use of Tamoxifen or Megestrol Acetate for palliation. Consistent with the findings in 
this study, ER and PR expression has been shown to be less common in high-grade 
lesions such as FIGO grade 3 endometrioid adenocarcinomas,112 clear cell carcinomas 63 
244
 and carcinosarcomas.245 246 Uterine papillary serous carcinoma are described as 
largely negative for ER/PR.247 248 
 
This study reveals that ER/PR values for UPSC+CC carcinoma are both low and of no 
significant difference in overall rates of expression between G3 EEC and UPSC+CC 
were found. These results are supported by investigations of Reid-Nicholson et al. as 
well as Soslow et al. who found no difference in ER/PR expression between G3 EEC 
and UPSC.112 120 248 Unlike findings by Oreskovic et al who proposed PR as a marker 
for survival, the data of this study did not show any survival benefit in the presence or 
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absence of ER or PR expression.249 P53 mutation is common in endometrial 
carcinomas123 124 and is reported to be the most characteristic genetic alteration of non-
endometrioid endometrial carcinomas.36 37 Also it is said that p53 evaluation is a useful 
tool to distinguish non-endometrioid carcinoma from endometrioid endometrial 
carcinomas.37 152 P53 positivity in G3 EEC in published literature varies between 10 and 
69%. Figures for p53 positivity in serous carcinoma are higher, ranging between 50 and 
93%.26 34 124 152 250 251 This study shows p53 positivity in the G3 EEC group of 19.1% 
and 31.6% in the UPSC+CC group, which was not statistically significant. This is in 
keeping with observations by Zheng et al. and Kounelis et al.124 250 Whilst some reports 
have suggested that p53 overexpression was the strongest prognosticator of survival, as 
determined by multivariate analysis, this study could not reproduce such findings, in 
fact p53 expression had no influence on survival. 252 253  
 
Particularly in view of p53 expression in USPC+CC, data from this study reveal lower 
values than in the wider literature. Two pathologists independently re-diagnosed all 
tumour specimens following retrieval of the blocks. We also explored other possibilities 
that could explain these results. Technical causes for different expression results could 
also be considered. However, in view of the immunohistochemical staining procedure 
of p53 the widely used clone DO-7 (DAKO, High Wycombe, UK) was chosen to avoid 
this potential bias. Furthermore standard operating procedures for staining were used by 
experienced laboratory staff. Another reason for inconsistencies regarding expression 
estimates between reports may be due to different criteria for p53 overexpression and 
scoring. Whilst this study used the H-scoring system 229 230 254 thus incorporating both 
intensity of staining and the local proportion of intensity producing a score from 0 to 
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300 (>150 = positive), other groups defined positive p53 expression in tumours when 
>10% of counted cells were stained 37 or when >50% of cells were diffuse or strongly 
stained. Unfortunately there is a considerable variety of scoring techniques in use 
rendering comparison hazardous. It has been advocated to use p53 as a diagnostic tool 
to differentiate between UPSC and EEC.124 152 Thus, we believe that the data of this 
study are robust. The results of this study demonstrate that a clear differentiation 
between UPSC and G3 EEC via p53 cannot be made.  
 
Her-2 expression was not found to be significantly different between the tumour types. 
HER-2/neu overexpression or amplification is found in non-endometrioid endometrial 
carcinoma with a variance between 18 and 80%.114 In endometrioid adenocarcinomas 
this has been reported in 9–30% and has been associated in some studies with an 
adverse prognostic outcome and linked to decreased overall survival.36 37 However, the 
findings of this study are more consistent with, Morrison et al who found a significant 
difference in Her-2 expression amongst non-endometrioid versus endometrioid 
endometrial cancers with similar expression rates between UPSC+CC (41.79%) and G3 
EEC (29%).153  
 
In conclusion, the data of this study suggest that grade 3 endometrioid carcinomas (G3 
EEC) have a similar immunohistochemistry and survival profile to what are considered 
more aggressive endometrial cancers and may be more suitable for inclusion into the 
type 2 group of endometrial carcinomas. If confirmed by larger studies, this has 
significant implications on the management of grade 3 endometrioid endometrial 
cancers. UPSC/CC tumours are frequently managed with adjuvant chemotherapy in 
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recognition of its systemic spread whereas G3 EEC tumours are treated with adjuvant 
radiotherapy only. The question arises whether adjuvant chemotherapy for G3 EEC 
should be considered if outcomes in both groups are similar. The currently recruiting 
PORTEC 3 trial is evaluating pelvic radiotherapy on its own with radiotherapy plus 
concurrent and adjuvant chemotherapy in women with high risk early stage and any 
advanced stage endometrial carcinoma. in a pooled group of grade 3 EEC and UPSC 
and CC cancers and will no doubt shed light on the differences in survival between 
these 2 groups in a robust prospective trial.255 
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4.4 Discussion of results for CD151 
 
This is the first study to evaluate the staining and prognostic significance of tetraspanin 
CD151 in endometrial carcinoma.240 Tetraspanin CD151 was selected as a marker 
suitable for investigation based on studies in breast cancer. Fedor Berditchevski’s 
laboratory group at the School of Cancer Sciences at the University of Birmingham 
found an increased CD151 expression in a subgroup of invasive ductal carcinoma 
showing a positive correlation with higher tumour grade and node metastasis. Thus they 
highlighted the potential prognostic utility of CD151 as a significant marker in a 
subgroup of poor outcome carcinoma of the breast.185 186  
The results of this study show that CD151 is an independent marker for DSS and RFS 
in poor outcome endometrial carcinoma by univariate analysis and for a triple negative 
subgroup of patients by multivariate analysis. CD151 is also differentially expressed, 
with highest expression in the UPSC and CC histology types. Contrary to expectations, 
it was found that high CD151 expression was positively correlated with improved 
survival. Thus, this is the first report, which suggests that expression of this tetraspanin 
protein in tumours may prevent transition to a more malignant phenotype.240 
In addition to observations made in breast cancer tissue CD151 has also been validated 
as a significant prognostic marker of outcome in other tumours. Ang et al. showed that 
overall survival was reduced in prostate cancer cases where CD151 was over 
expressed.187 This was consistent with findings in lung cancer patients.188 In colon 
cancer changes in expression of CD151 appear to be more complex. An early report 
described that increased expression levels of tetraspanin correlated with a more 
advanced stage of the disease.180 However, a more recent study found that expression of 
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CD151 protein was reduced in human colon cancers compared with surrounding normal 
tissue, in which it is strongly expressed on the basal and lateral surfaces of epithelial 
cells.190 The authors hypothesised that intra-tumoural activation of hypoxia-inducible 
factor 1 (HIF-1) led to inhibition of CD151 expression and this repressed the function of 
E-cadherin, thereby dramatically reducing cell-to-cell adhesion and thus increasing 
invasion and metastasis. 190 Interestingly, it was also found that expression levels of 
CD151 in the metastatic lesions were increased when compared to primary colon cancer 
tissues. 
Although the exact biochemical function of CD151 is still unknown, evidence shows 
that it is involved in signal transduction 256 257, cell adhesion 258, and motility.181 In 
relation to tumour metastasis, the experiments using anti-CD151 mAb have established 
that tetraspanin CD151 may contribute to an early step in the formation of secondary 
metastatic lesions by mediating invasiveness of primary tumour cells into surrounding 
stromal tissues and vascular intravasation.181 More recently, the study group of Fedor 
Berditchevski has shown that CD151 can also regulate recruitment of breast cancer cells 
to the lungs and growth of the metastatic lesion.259 Thus, it appears that tetraspanin 
CD151 may be involved in various aspects of the metastatic cascade.    
Although the results of this study strongly suggest that CD151 may play an important 
role in tumourigenesis in a particular type of endometrial cancer, the mode of its action 
remains unknown. Holcomb et al. examined E-cadherin in endometrial carcinoma and 
found that papillary serous and clear cell carcinomas show significantly reduced E-
cadherin expression in comparison with endometrioid tumours.260 Thus, one possibility 
might be that CD151 counteracts the metastatic progression or development of more 
aggressive forms of endometrial cancer by stabilising E-cadherin based cell-cell 
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interactions. In this regard, it is noteworthy that this study found a strong correlation in 
the expression levels of E-cadherin and CD151 in cancer samples. Alternatively, CD151 
may act through laminin-binding integrins, its main molecular partners in tetraspanin 
microdomains, by strengthening interactions of endometrial cells with laminin 
components of the basement membrane. Detailed immunohistological analyses of 
normal endometrial tissue, endometrial hyperplasia and all grades and stages of 
endometrial cancer tissues will be necessary to address this issue in the future.  
 
So far treatment options in type 2 endometrial cancers are largely limited to surgical- 
and/or chemotherapy regimen, which have not altered the poor prognosis of these 
tumours. 
There is an unmet clinical need for robust prognostic markers that can help in guiding 
therapeutic decisions in these endometrial tumour types, particularly at recurrence and 
in advanced stage tumours, given poor response rates to chemotherapy and to identify 
new therapeutic targets. Currently advanced stage, poor prognostic endometrial cancers 
pose a dilemma in management and given poor response rates to chemotherapy are 
treated with palliative measures.  
This study suggests that, in patients with CD151 positive tumours, survival is 
significantly better than those with CD151 negative tumours. This may allow for more 
rational prescribing of adjuvant chemotherapy in advanced stage type 2 cancers. It could 
also be clinically relevant as even in a triple negative marker group, CD151 is highly 
prognostic of both DSS and RFS.  
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An enhanced understanding of the molecular basis of these tumours will also aid in the 
development of novel, targeted therapies and treatment modalities against these 
aggressive types of endometrial cancer. Identification of patients with endometrial 
tumours having adverse clinical and molecular prognostic characteristics may also 
facilitate adjuvant therapies aimed at improving outcome.  
 
The results of this study suggest the possibility of the usefulness of tetraspanin CD151 
as a prognostic marker in some forms of poor outcome endometrial carcinoma. 
However, to confirm this it is necessary to assesss CD151 expression patterns in lower 
grade endometrial tumours, its precursor lesions and in normal endometrial tissue and 
compare its findings with the expression patterns such as were found in this cohort of 
high grade poor outcome endometrial cancers. 
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4.5 Discussion of results for Clusterin 
 
This is the first study to evaluate the staining and prognostic significance of the so far 
poorly understood clusterin (CLU) as a clinical marker in grade 3 endometrial 
carcinoma.  
CLU has been shown to play a role in a range of physiologic cell functions such as cell 
cycle regulation, cell adhesion, tissue remodelling, and immune system regulation but 
also pathologic processes such as carcinogenesis and tumour progression where it has 
been described to have both pro-apoptotic and anti-apoptotic properties.197 219 261 262   
Leskov et al. proposed that in a response process to cell damage CLU is expressed to 
induce apoptosis. 263 Conversely CLU has also been observed as acting anti-
apoptotic.195 Also, over- and underexpression has been observed in a variety of cancer 
tissues suggesting multiple mechanisms of induction or control of clusterin function.  
 
In the three histological groups of this study clusterin appeared to be overexpressed 
between 48% (G3 EEC) and 60% (UPSC+CC) with no significant difference between 
them. The overexpression of clusterin in UPSC+CC histology may be seen in contrast 
with the only other study investigating clusterin expression in endometrial cancer 209 
where CLU showed increased expression in endometrioid type but not in UPSC type 
histology. However, Ahn et al. evaluated only 7 tumour specimen with UPSC histology 
whilst the remaining 81 specimen were of grade 1 and 2 endometrioid histology, none 
of grade 3. They also used a quantitative scoring system recording only the surface-
percentage of stained tissue with an according score of 0 to 3. The H-score used in this 
study additionally incorporates the intensity of staining. Given that 34 out of 81 
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specimen in Ahn’s cohort had a score >1 this is not far off the findings of this study in 
grade 3 endometrial carcinoma. Contrary to Ahn’s findings, particularly in view of the 
similarity of Ahn’s findings in grade 1 and 2 histology compared to the scoring levels of 
this study, the expression results of this study do not appear to be histological type 
specific. Similar to Ahn’s results this study was unable to find a relationship between 
clusterin levels and tumour stage.  
With these results the biological role of Clusterin in over- or under expression in 
endometrial cancer, whether anti-or pro-apoptotic, remains so far unclear. 
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4.6 Discussion of the findings in the sarcoma+ 
carcinosarcoma+ mixed histology group 
(group III) 
 
Group III showed a significantly shortened survival in comparison with the other two 
groups with a disease specific survival of 2,7 years (0.05-11.43) in comparison with 4.6 
(G3 EEC, range 0.01-11.79) and 4.7 (UPSC+CC, range 0.07-10.33) years (p<0.001). 
Thus, in the multivariate analyses the sarcoma/MMMT/mixed group maintained 
together with age and stage its statistical significance as a predictor for poor survival 
(Table 3.6 see page 127). Interestingly all marker expressions assessed including p53, 
Her-2, ER and PR expression were very low or negative. Given the fact that 
carcinosarcoma (MMMT) are normally partially composed of carcinomatous elements 
of endometrioid or serous type a certain frequency of marker expression changes could 
have been expected. However none of the nine cases of MMMT of this study expressed 
p53, Her2 or ER. While other studies were also unable to identify any high numbers of 
mutations in this subtype,264 McConechy et al. observed mutations in the TP53 gene as 
high as 64.3%.52  
CD151 expression results in the sarcoma/MMMT/mixed group, consistent with the 
findings in this study of an inverse correlation to survival, were significantly lower than 
in the UPSC+CC group. There are no reports in the literature about CD151 expression 
and any of the tumour tissue collated under this group heading. 
 
Clusterin expression in group III were 48.0% and showed no significant difference to 
the other 2 groups. In detail 7 of the 13 sarcoma tissues, 5 of the 9 MMMT tissues and 0 
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of the 3 tissues with mixed histology showed an overexpression of clusterin. There is no 
report in the published literature about clusterin behaviour in one of these tumour 
groups. Although there are reports about strong clusterin expression in other sarcoma 
tissues such as follicular dendritic tumours 265 group III of this study is possibly 
biologically too heterogenous and the absolute numbers of each tumour group too small 
to draw any conclusion out the findings.  
 149 
 
4.7 Discussion of Tissue microarray (TMA)  
 
4.7.1 Highlighting the utility and advantages of TMA 
The power and utility of TMA technology is manifold. It is a rapid, tissue saving and 
cost effective high throughput technology. The pathologist has only once to collect, 
scrutinize and choose the tissue specimen from which the tiny tissue cores are extracted 
which in turn are then available for a multitude of tests and assays. It not only decreases 
the volume per assay exponentially, to the contrary, without destroying the original 
blocks for diagnosis, scarce tissue is amplified and simultaneously experimental 
uniformity provided due to the fact that a multitude of tissue specimen on a single 
block/slide is exposed to identical processing conditions. Once constructed, the TMA 
block can be sectioned potentially hundreds of times, with each section providing a 
fully annotated cohort of tumours that is ready for biomarker analysis. The logistical, 
economical and time advantages provide laboratories with the opportunity to include 
several thousand of patient samples into a single TMA which impacts positively on 
scientific and statistical quality and reliability.266 
 
4.7.2 Discussion of potential risks in TMA technology  
There are a few distinct weaknesses in TMA technology. In view of the small size of 
tissue assayed the results are dependent on excellent quality of tissue sampled when 
constructing the TMA, highly standardized laboratory techniques and appropriately 
validated antibodies.267 Frequently in TMAs large numbers of specimen are required at 
the same time. Thus, there is a greater risk of using potentially aged material which has 
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sometimes been stored for many years or has been processed differently prior to storage. 
In this study tissue specimen were used being up to 12 years in storage. To which 
degree this impacted on antigenicity and validity of marker expression in this study is 
unknown. 
The impetus of TMA construction and subsequent slide production is maximising the 
number of cores in a TMA block and slides cut per block. The smaller the tissue cores, 
the denser the stacking in the block and the thinner the slices cut the greater the risk of 
loss of tissue cores and tissue antigenicity. 
To avoid such problems TMA construction recommendations were followed in a way as 
have been recently summarised and presented by Dr Heike Grabsch, senior clinical 
lecturer and consultant histopathologist in GI Pathology at the Leeds Institute of 
Molecular Medicine.268 Sufficiently deep plastic molds were used for the wax block 
casting with wax containing plastic polymers to prevent excessive expansion and 
shrinkage with temperature changes. Furthermore, ‘low density’ TMAs were 
constructed with sufficient space around the outer row of cores and 1 mm spacing 
between each core. TMA blocks were cut perpendicular to the short axis of the block at 
room temperature to avoid block breakage and distortion, folding or disintegrating of 
cut slices. For the placement of each cut slice onto the slide, the ‘tape transfer 
sectioning’ technique was employed with the advantage of having virtually no section 
or core loss. Only after the completion of TMA construction for this study Catchpoole 
et al published observations of nonspecific immunohistochemical staining artifacts due 
to tape transfer technique.269 It does pose an additional risk regarding the validity of our 
staining results particularly since Clusterin and CD151 have not yet been validated in 
endometrial cancer tissue. 
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4.7.3 Discussion of validity and representativity of the TMA 
technique 
Like in this study, TMA research results are based on findings on tissue cores as small 
as 0.004 mm x 0.6 mm or even smaller. When TMA’s were first introduced questions 
were raised regarding the validity and representativity of this technique generally and in 
view of the size and number of tissue cores used per specimen based on the assumption 
that conventional whole sections are/were the gold standard for molecular tumour tissue 
analysis and representativity. There are several publications advocating between one 
and four cores per tumour specimen per TMA. There are a number of clinically well 
established markers such as Her2 in breast cancer, Ki76 in breast and urinary bladder 
cancer and vimentin expression in kidney cancer advocating the sufficiency for a single 
core.270-273 Other studies have concluded that multiple cores such as 3–4, offer 
advantages over a single core also in view of the potential heterogeneity of tumour 
tissue within the same specimen. One practical rationale of demanding more than one 
core is that if individual cores are washed out during the slide-processing the tumour 
specimen is still likely to be represented by the „back up core”.274 275 However, to avoid 
a bias it is important to limit analysis to samples with identical numbers of spots used 
for interpretation or to one spot per individual tumour specimen only. In this study it 
was decided to use two cores per tumour specimen.  
There is no consensus as regards the size of the tumour cores. Sauter outlined 0,6 mm 
cores have been used widely and offer the practicability of being small enough to allow 
large enough numbers of cores being placed on the same TMA. Also, 0,6 mm cores are 
small enough to detect and count individual tumour cells whilst larger cores 
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unnecessarily carry a risk of having a higher proportion of non-neoplastic cells thus 
increasing the variability of the amount of cancer tissue analyzed per specimen. Cores 
less than 0,6 mm are certainly more economical in terms of TMA space needed. 
However, they are technically more difficult to handle, due to sampling-needle size and 
specimen-needle friction and cores are also more likely to get lost during the various 
steps of the TMA production.276 Altogether, there seems to be now sufficient evidence 
of strong correlation between TMA histospots and whole-tissue sections provided there 
are at least two adeaquately represented cores of 0.6mm diameter.277  
In view of TMA validity it has been well documented that TMAs can reliably reproduce 
well-established associations between molecular changes and clinico-pathological 
parameters.270 271 278 Ruiz et al. proved in a TMA study of more than 1,900 breast 
cancers the reproducibility of the well established prognostic relevance of the 
heterogeneous proliferation marker Ki-67 expression.270 Jaquemier et al. studied the 
expression of 26 proteins by immunohistochemistry on TMAs containing more than 
1,600 cancer specimens from 552 patients with breast cancer and controls. There was a 
high degree of concordance between immunohistochemistry on full sections and on 
TMA (p<0.0001).  
Furthermore they not only observed clustering of expression profiles which correlated 
correctly with phenotypic tumour classification but developed a TMA-based protein 
expression signature that classified patients into two classes (good prognosis and poor 
prognosis) with a highly significant difference in 5-year MFS (90% versus 61%). The 
findings were validated in an independent set of >180 patients, proving its robustness. 
In multivariate analysis, the protein expression signature was the strongest independent 
predictor of clinical outcome. At the 2012 Biomarkers, Biostatistics and Novel Clinical 
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Trial Design workshop in Nottingham Prof I. O. Ellis presented results from a 24 
marker expression analysis based on a TMA of tumour specimen of 1024 primary 
operable breast cancer cases.279 The subsequent hierarchical clustering of expression 
profiles not only correlated highly with the known clinical outcome of the patients but 
the findings were broadly comparable to clusters described in previous cDNA based 
clustering studies.  
The coupling or extension of cDNA arrays with TMAs is certainly a luring new 
development and has been successfully done for the possibility of discovering clinically 
relevant, potentially new proteins by first observing a certain gene amplification 
measured by fluorescence in situ hybridization and then successfully correlating it with 
a certain protein overexpression measured by IHC on a TMA. However, it has been 
previously described that specimen showing IHC detectable protein expression levels 
may be encoded by very low levels of RNA, that is below the detection level of cDNA 
arrays. 280 Conversely it is possible that a chosen antibody may only detect certain forms 
of a protein that do not correspond to the cDNA spotted on the DNA array.  
In summary there are important lessons to be drawn for current interpretation as for 
further studies. First, gene expression analyses may not correlate with corresponding 
protein expression analyses. Ideally, where possible, both should be performed. If 
results do not immediately correspond, the may both inspire for further thinking. TMA 
results of novel markers should be taken with caution since there are a number of 
technical or biological factors that may have confounded the observed results. If for 
instance the antibody concentration is low only high or higher expression levels will be 
detected which might blur the clinically relevant cut off level of the expressed protein. 
The TMA’s inherent reproducibility lends itself to the opportunity to test a range of 
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antibody concentration levels at the same time. However, results of which are 
particularly difficult to interpret when investigating a novel marker. 
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4.8 Methodological considerations 
 
A controversial issue for this study was the infrequency of pelvic lymph node sampling 
during the operation despite their allocation to a high risk group. However; as 
mentioned above this was consistent with surgical practice in the United Kingdom, in 
the study time period. Patients without gross peritoneal disease and lymphadenectomy 
were staged according to the extent of uterine involvement. Indeed, the need for pelvic 
and para-aortic lymphadenectomy however remains a topic of debate among 
gynaecologic oncologists.281 There is still a lack of consensus if at all or in which 
endometrial cancer type, grade and stage precisely, and to what extent surgical staging 
should be performed. There is even more controversy about the therapeutic and 
prognostic effect of it. If at all, increasingly both bilateral pelvic and para-aortic 
lymphadenectomy is advocated because positive lymph nodes appear to be common in 
all grades.282 Given the likelihood of partial under staging due to non-assessed 
lymphnodes the question remains how many patients were not accurately stratified into 
the respective stages and thus treated. However, the survival data in this study 
demonstrate that ‘stage’ remained an independent prognostic marker for survival even 
in the multivariate analysis, which supports the likelihood of near accuracy of the 
staging procedure applied.  
 
Regarding the construction of the tissuemicroarrays (TMAs) the present study would 
have been greatly strengthened by including low grade endometrial cancers and normal 
endometrial tissue as controls. This would have provided the opportunity to demonstrate 
a potentially progressive effect of some of the markers investigated across the range 
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from healthy endometrium to aggressive serous carcinoma. In particular, for the G3 vs. 
UPSC/CC study, this would have allowed for a more comprehensive comparison which 
was already recognised by Zannoni et al. in a commenting letter to the editor after the 
publication of some of the results of this study.283 Indeed, this would have potentially 
strengthened further the findings of the close relationship between G3 and UPSC/CC 
histology in this study. 
 
Concurrently, particularly in view of the fact that this study is among the very first to 
describe expression patterns of both CD151 and clusterin in endometrial carcinoma, it 
would have been of great interest within this study as well as for the wider research 
community to demonstrate expression patterns of these markers on normal endometrial 
tissue and all types and grades of endometrial neoplasia. Additionally it would have 
been interesting to complete the findings in TMA cores with expression patterns in fresh 
endometrial and tumour tissue. Additionally, such studies would enable the production 
and use of antibody dilutions optimised for endometrial tissue, rather than breast tissue 
as used in this study. 
 
At the outset of this study it was intended not only to read and score the TMA cores 
manually but also in an automated fashion, thus compare expression results in order to 
both estimate the validity of the manual reading as well as improve the overall quality 
with an additional human observer-independent test. However, logistical problems, the 
novelty of the markers used and the considerable effort and costs involved rendered this 
plan impossible. 
 157 
 
Currently, a major issue most studies face when involved in IHC evaluation of markers 
is the significant variability in the scoring process, which can also partly explain the 
results of this study. Such variability originates mainly from three factors, the staining 
process, the individual assessment of the person(s) “reading” the cores as well as the 
scoring algorithm used. Obviously such inevitable but confounding factors render the 
validity and thus inter-study comparability of any findings difficult. Thus, it is hugely 
vital to achieve standardisation in these procedures that will produce robust results.  
As William Gallagher’s group of the UCD Conway Insitute in Dublin have repeatedly 
demonstrated described and proven, the option of whole slide scanning and automated 
analysis of the digital images produced makes it possible to recognise and differentiate 
normal from tumour tissue. Employing decision tree models using a multi-fold cross-
validation approach, image analysis algorithms are also able to precisely assess quality 
and quantity of expression of any given marker, calculate prognostic subgroups and 
identify optimum thresholds for survival analysis.284 285 Such scanners assess all 
available cores with precisely the identical accuracy, 24 hours a day, in a fraction of 
time needed for individual scoring obviously entirely inter- and intra- observer 
independent. In a time where a sheer unfathomable number of markers identified await 
evaluation and validation to be hopefully implemented in the future as effective 
personalised cancer therapeutic regimes, it is likely that the manual assessment and 
scoring of marker expression will soon be an exercise of the past.  
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4.9 Suggestion of Further Studies 
 
More detailed investigations in a larger cohort would be useful to support the proposal 
of the close clinical and prognostic relationship between grade 3 endometrioid 
endometrial carcinoma and uterine papillary serous and clear cell carcinoma. 
 
In view of validating the findings of CD151 and its prognostic significance a larger 
prospective study in this group of cancers is now being established. However, at the 
same time it is vital to investigate this marker in normal endometrial tissue, precursor 
lesions and lower grades of endometrial carcinoma to establish its true relevance as a 
prognostic or diagnostic marker in poor outcome endometrial carcinoma. 
Additionally it would be interesting to be able to benefit from large collections of 
appropriate tumour specimen such as stored tissue blocks from randomized controlled 
trials such as PORTEC 3.  
 
Finally it would be hugely interesting to re-capture the TMA slides using a slide scanner 
and process an automated image analysis for re-evaluation of the expression patterns 
produced through this study. 
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